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Executive Summary 
 
Capstone Project Title 
Reducing Variability Among Multiple Operators Using a Single Technique and Device for Skin 
Prick Testing in Children 
 
Problem 
The variability in performance among skin prick test (SPT) operators who performed the twist 
technique versus the prick technique was raised within the Pediatric Program at the Study Site. 
Confidence in the SPT results was threatened, treatment plans were delayed and diets remained 
restricted. 
 
Purpose 
This Doctor of Nursing Practice (DNP) Capstone Project was designed to identify a single device 
and technique that could be used at the facility to reduce variability, increase reliability, and 
standardize the skin prick test procedure using a single technique and device within the 
institution. This inexpensive test has the potential to yield enormous results at a single visit and 
dictate life saving treatment, which is patient specific. 
 
Research Study Objectives 
The PICO (Population, Intervention, Comparison, Outcome) research question asked: (P) 
Among children ages 1 year through 16 years receiving skin prick testing for diagnosis and 
treatment of their allergic disease, (I) does the Quintip device puncture technique or Duotip 
device twist technique (C) when compared to the Duotip prick technique (O) decrease variability 
and increase reproducibility of results when conducted by multiple operators? The Capstone 
Project successfully identified a single technique and device to be used by multiple operators to 
provide high quality, reliable, and valid allergy skin testing results for at-risk patients.   
Research Methods and Procedures 
This DNP Capstone Project was a prospective, double-blind clinical trial using a convenience 
sample in which pediatric research participants underwent SPT in a single session, with a single 
operator using the Duotip twist and Quintip puncture techniques as compared to the Duotip 
prick/lift technique. 
 
Study Results 
Comparing results between the three techniques and two devices, the Quintip twist method was 
most sensitive (97%) as compared to the punch technique (86%) and prick/lift technique (89%). 
Only 2.8% of those tested using the twist technique produced false negative responses to 
histamine as compared to 14% (Quintip punch) and 11.1% (Duotip prick/lift). 
Implications for Practice and Future Research 
As new SPT technique and devices are introduced, ongoing research will be necessary to 
evaluate variability and respoducibility among operators, to ensure improvements in diagnosis 
and treatment food, drug and environmental allergies can be achieved. 
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Reducing Variability Among Multiple Operators Using a Single Technique and Device for Skin 
Prick Testing in Children 
 The United States Department of Health and Human Services- National Center for Health 
Statistics (2013) reported a significant increase in the prevalence of food allergies in children 
under the age of 18 years living in the United States during 2009-2011 as compared to 1997-
2009. Skin prick testing has been used as a diagnostic tool since first described in the literature in 
1873 when Dr. Charles H. Blackley scratched the skin on the forearm with a lancet and wet lint 
saturated in grass pollen to diagnose chronic allergic rhinitis when a whealing response occurred 
at the site (Krau and McInnis, 2010). This inexpensive, minimally invasive test can be conducted 
in an outpatient office setting and is highly dependable when performed correctly (Cox et al., 
2008). However, if not performed correctly false positive and false negative results can occur 
and treatment plans may have life threatening consequences. The purpose of this research study 
aimed to identify the single skin prick test technique and device that allowed for the greatest 
reproducibility and decreased variability among multiple operators performing skin prick test 
procedure in the pediatric population at the study site. 
Problem Recognition and Definition 
Background and Significance of Problem 
 At the study site, medical providers evaluate and treat pediatric patients with a variety of 
allergic, rheumatologic and immunologic disorders of childhood including pediatric asthma, 
exercise-induced asthma, hives, allergies, food allergy, stinging insect allergy, anaphylaxis, 
atopic dermatitis, immunodeficiency, recurrent infection, chronic cough, vocal cord dysfunction, 
and illnesses which may complicate chronic allergic disease such as gastroesophageal and 
laryngopharyngeal reflux (NJH, 2013). The study site brings together a team of America's best 
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and highly skilled pediatric physician specialists, nurses, dietitians, psychosocial clinicians, and 
ancillary team members. The comprehensive team approach is designed to provide accurate 
diagnosis, develop individualized treatment plans, and deliver in-depth education to address the 
specific needs and goals of each patient. 
 A common diagnostic procedure performed during the initial evaluation and on-going 
follow-up care is the skin prick test. This test involves placing allergen solutions on the skin and 
then pricked using a disposable device. The results of the SPT provide valuable information used 
to confirm diagnoses and develop treatment plans (Cox et al., 2008). According to Cox (2008), 
the SPT remains the preferred diagnostic technique for allergy because results are quickly 
available, allows for evaluation of multiple allergens at a single office visit, and has a good 
correlation to in vitro (serum IgE) testing. Visually, the SPT can provide a graphic representation 
of the sensitivity for the allergen as compared to the saline and histamine controls. In addition, 
less common allergens, such as local fruits and vegetables or certain brand name medications, 
can be specifically tested using the SPT technique when no specific IgE antibody serum 
measurements are available (Heinzerling et al., 2013). 
 The United States Joint Council of Allergy, Asthma and Immunology (2013) and the 
European Academy of Allergy and Clinical Immunology (2013) highly recommend 
percutaneous SPT as the primary tool for diagnosing allergic disease. Skin prick testing is a key 
test in identifying allergens causing allergic symptoms, prescribing immunotherapy treatment, 
and defining avoidance diets. As a result, physicians and health care providers must be confident 
in the SPT results as they construct their medical diagnoses and treatment recommendations. 
False positive findings may occur if the operator presses the SPT device too hard against the 
skin, causing erythema from technique versus true allergic response to antigen (Carr, W. et al., 
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2005). On the other hand, the operator may not press the SPT device hard enough against the 
skin so the antigen cannot penetrate the epidermis, leading to a false negative finding. Patients 
may end up being exposed to allergens that they are highly allergic to and subsequently have life 
threatening reactions when allergens are unknowingly introduced.  
 New SPT devices continue to be developed including multihead devices, which allow for 
application of several antigens simultaneously; however, these have been difficult to use in the 
pediatric population at the study site. Children have a tendency to move unpredictably during the 
procedure and multihead devices can cause variation in penetration of allergens across the 
placement region on the back (Carr, 2005). Locally, the preferred single head tool is the Duotip 
device using the prick-lift technique and the twist technique. However, for this DNP Capstone 
Research Project, the researcher also used the single head Quintip device employing the punch 
technique to assess reproducibility and variability among multiple operators. 
 In Fall 2013, the health care team at the study site noted increased variability of SPT 
results among multiple operators.  Before permitted to conduct the SPT procedure at the facility, 
Certified Nursing Assistants and Registered Nurses had to successfully pass a written test and 
demonstrate performance competency using their technique choice and read/record results with 
100% accuracy. When concern about the SPT was raised at the facility, data was collected 
including the technique each operator used, the number of previous tests performed, and the date 
initial SPT education and training were completed. Results revealed the operators were trained 
and deemed competent on one SPT technique but now were using another technique. Placement 
of allergens on skin varied between operators and reading of results varied up to three minutes- 
from 15 to18 minutes (Esterl, 2013). Immediate actions to increase the reliability and reduce 
variability of results included repeat education and training for all operators before further SPT 
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was permitted, significantly limiting the number of operators performing the SPT procedures, 
and restricting the technique to the twist technique using the Duotip device.  
 This DNP Capstone Research Project aided in identifying the single technique and device 
needed to further limit variability and increase reliability of the SPT results when conducted on 
children by multiple operators at the study site. According to the Allergy Diagnostic Practice 
Parameter (Bernstein, 2008), "The reliability of prick/puncture tests depends on the skill of the 
tester, the test instrument, color of the skin, skin reactivity on the day of the test, potency, and 
stability of the reagents"(p 56). Health care providers must be confident in the results of the SPT 
to assist in the diagnoses of food, environmental and drug allergies and develop a trustworthy 
treatment plans for pediatric patients seen at the facility.  
Statement of the Research Problem 
 Increased variability in SPT results was noted by the medical providers at the facility 
when multiple operators conducted the SPT using the twist and prick techniques. Confidence in 
the SPT results was threatened, treatment plans were delayed and diets remained restricted. The 
goal of this DNP Capstone Research Project was to identify a single technique and device to 
standardize the SPT procedure, reduce multiple operator variability and improve reproducibility 
among the pediatric patients seen at the study site. 
Statement of the Research Study Purpose and Aims  
 The purpose of this research study was to compare the variability of Skin Prick Test 
(SPT) results of the Duotip twist and Quintip puncture techniques as compared to the Duotip 
prick/lift technique when carried out on the backs of the pediatric participants by multiple 
operators. Specifically, this Doctor of Nursing Practice (DNP) Capstone Research Project was 
intended to evaluate reliability and variability of the SPT techniques and devices used by 
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multiple operators in order to identify the superior single technique and device to be use by all 
operators at the study site. With these results, physicians will be able to make accurate diagnoses 
and treatment care plans for their highly allergic pediatric patients.   
Aims related to SPT techniques and devices included: 
1. To determine the variability of each SPT technique and device using multiple operators. 
2. To determine the reliability of results using multiple operators and different SPT 
techniques and devices. 
3. To determine the single SPT technique and device to be used by all operators in the study 
site 
Literature Review/ Selection Process/ Summary 
 The focus of the systematic literature review was to assess the use of single-head SPT 
devices and variability of results when performed by multiple operators in the pediatric 
population. Six electronic databases searched included: PubMed, ClinicalTrials.Gov, CINAHL, 
National Center for Biotechnology Information, Cochrane Database of Systematic Reviews 
(CDSR) and Database of Abstracts for Review of Effectiveness (DARE). Initial searches were 
restricted to English language articles published between 2002-2013. However, dates were 
expanded to 1980-2013 to increase the number of research studies and reports used to confirm 
previously published research on the SPT techniques and devices, regardless of the age of 
participant. Searches included research conducted in the United States and throughout Europe as 
long as it met all other criteria. 
 The terms used in the database searches included: food allergy, immunoglobulin E, SPT, 
children, operator variability, allergy, sensitization, food allergens, eosinophil esophagitis, 
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allergies, Type I, diagnostic test asthma, Duotip, Lancet, Quintip, and oral food challenges. The 
search resulted in 30 reports as follows: 
  1    Cochrane systematic review  
 The Cochrane systematic review included electronic searches of PubMed, Cochrane 
Database of Systematic Reviews, Cochrane Database of Abstracts of Review and Effect, and 
Cochrane Central Register of Controlled Trials. Searches were limited to English language 
articles indexed between January 1988 and September 2009. A total of 12378 citations were 
identified and two investigators reviewed 72 citations independently, using the AMSTAR 
criteria, the quality of the studies using the QUADAS criteria relevant to food allergy, and the 
quality of the randomized controlled studies using the Jadad criteria (Chafen et al., 2010). 
 13   Well-designed randomized controlled adult trials 
 10   Well-designed controlled adult trials without randomization 
 6    Evidence from systematic reviews of descriptive or qualitative studies 
 A review of the 30 reports revealed the use of SPT as the primary diagnostic tool for 
allergy evaluation.  However, this review revealed only one study that focused specifically on 
children (Illi et al., 1998) and one study that included adults and children that compared SPT 
with another diagnostic tool to identify and treat allergies in patients, but did not address operator 
variability or reproducibility (Mehl, Niggemann, Keil, Wahn, & Beyer, 2012). Illi et al., (1998) 
examined the variability of SPT testing performed by four different operators on 28 pediatric 
subjects ages 6 years to 14 years. Researchers tested 16 children using the multihead device and 
lancet on the forearm and found the lancet to be superior with operator reproducibility. The 
remaining children were only tested with one device, 11 children were tested with the multihead 
device and one child was tested was the lancet. Illi et al., (1998) noted "the skin prick tests 
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applied by the four fieldworkers resulted in small, by statistically significant differences in their 
outcomes" (pg. 357, para 1). This was the only study found during the review process that 
focused specifically on multiple operator variability and reproducibility when performing SPT 
on the pediatric population.  
 The remaining studies and reports from this systematic review focused on the adult 
population, which served to inform this DNP Capstone Research Project. Studies comparing the 
performance of commonly used SPT devices and techniques to achieve reproducible results 
revealed significant differences when the SPT was conducted on the forearms and backs of the 
adult participants (Carr, Martin, Howard, Cox, & Borish, 2005; Corallino, Nico, Kourtis, 
Filomena Caiaffa, & Macchia, 2007; Masse et al., 2011; Werther et al., 2012; Nelson, 
Kolehmainen, Lahr, Murphy, & Buchmeier, 2004; Nelson, Rosoniec, McCall, & Ikle, 1993).  
However, the sample sizes in all of these studies were small, ranging from 12 to 22 adult 
participants.    
  Four research studies on adults were completed (Nelson, Knoetzer, & Bucher, 1997; 
Nelson, Kolehmainen, Lahr, Murphy, & Buchmeier, 2004; Nelson, Lahr, Buchmeier, & 
McCormick, 1998; Nelson, Rosoniec, McCall, & Ikle, 1993) between 1993 and 2004 and 
included 53 adult subjects enrolled in three SPT device comparison studies evaluating quality, 
reproducibility, patient acceptance and one clinical study evaluating the distance between SPT 
sites and the quality of allergen extracts with 79 adult subjects. These studies reported that the 
SPT results varied greatly based on the SPT device used to conduct the test as depicted by the 
size of reactions to the positive (histamine) and negative (glycerol-saline) control solutions.  The 
investigators recommended that operators be competency tested with the SPT devices to 
establish testing baseline before allowing performance in the clinical setting. Furthermore, 
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Nelson, Rosoniec, McCall, & Ikle (1993), reported the greater the trauma from the SPT device, 
the larger the reaction to the histamine or allergan and the greater likelihood of a whealing 
reaction and less likelihood of a false negative reaction. In addition, single and multihead devices 
displayed a consistent and significant trend for larger wheals when performed lower on the back 
and are unlikely to cause a false positive reaction when placed apart at least 2cm from another 
prick site (Nelson, Knoetzer, & Bucher, 1997). 
  Carr et al., (2005) enrolled 20 adult subjects (13 subjects completed the study) into a 
study comparing the performance of four multihead SPT devices and four single-head SPT 
devices performed by a single operator and found significant differences between the two types 
of devices (p<0.008), with multihead devices demonstrating the greatest variability and more 
painful as compared to the single head devices. Skin prick test reactions using the multihead 
devices were larger when tested on the back as compared to the single head devices with larger 
reactions on the forearm. 
 In a study of 22 adults comparing the reproducibility and sensitivity of four SPT 
instruments with the use of a positive control, Masse et al., (2011) calculated interpatient and 
intrapatient reproducibility between each technique and found the 23G intravenous (IV) needle 
and metal lancet were superior (p < 0.01) when compared to the two Stallerpoint and 
Stallergenes prick lancet and methods.  
  Werther et al. (2012) reported in a research study that SPT results carried out by eight 
operators using four different single-head devices. The researchers concluded that the lancet and 
Quintip SPT devices using the punch technique had less variability among multiple operators 
than those using the prick technique with the Greer Pick and Feather Lancet. However, their 
sample size was small, five subjects in total and conducted with healthy adult volunteers.  
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 Regardless of the SPT device used, studies reported that the SPT caused minimal 
discomfort, offered a high yield of information, but had significant variability dependent on 
operator education and training (Carr, Martin, Howard, Cox, & Borish, 2005; Corallino, Nico, 
Kourtis, Filomena Caiaffa, & Macchia, 2007; Masse et al., 2011; Nelson, Lahr, Buchmeier, & 
McCormick, 1998; Werther et al., 2012). 
  In 2008, the American College of Allergy, Asthma and Immunology (ACAAI) and the 
American Academy of Allergy, Asthma and Immunology (AAAAI) developed a task force 
charged with developing the Allergy Diagnostic Practice Parameters (Cox et al., 2008). The 
guidelines offered a comprehensive review of diagnoses, tests, and procedures, and expected 
results for healthcare professionals caring for patients with allergic diseases for infants, children, 
and adults. The updated information included SPT technique instructions and suggested 
proficiency testing and quality assurance techniques for prick and puncture SPT (Cox et al., 
2008).  
 Based on the review of the literature, there was an identified need for research that 
focused on SPT testing in the pediatric population.  Therefore, this DNP Capstone Research 
Project aimed to contribute to understand of SPT testing in children and improve the quality and 
outcomes of care for the pediatric population.  
Theoretical Foundation for Study 
 Nursing is an important part of the study site and directed to serve the health care needs 
of children and their families. A general understanding of theoretical foundation and how 
theories impact evidence-based practices were essential in the success of this research project.  
 Change theory. A theory of change provided the framework to move from one point to 
another to achieve a goal. It differed from other theories by: 
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 Showed a pathway which time points and associated actions were needed to achieve 
goals 
 Underlying assumptions were required, tested, and measured 
 Changed the way of thinking from what was currently being done to what was wanted to 
be achieved 
 Kurt Lewin's three-step change theory. Universally, Lewin is known as the founder of 
modern psychology and pioneered the use of experimentation in testing the change hypothesis 
(Greathouse, 1997). In 1947, Kurt Lewin introduced the three-step change model. Lewin stressed 
the importance of not only defining the goals of the change, but also including supportive 
objectives to achieve during the change process to break the emotional bond noted at the initial 
starting point. The three-step change model of Lewin's includes: 
1. Unfreezing- The step is achieved by directing behavior away from the status quo, 
promote positive force that will facilitate change through trust and recognition, and 
actively participate in brainstorming solutions to achieve change (Lewin, 1947). 
2. Movement- Create movement by changing the status quo. This can be accomplished by 
providing new perspective with beneficial solutions, working together towards the new 
common goal and leadership supporting the change. 
3. Freezing- The third step reinforces the new behaviors and values that have been 
integrated into the community. The driving forces of change and the restraining forces are 
now stabilized and the combined forces are stronger. New policy and procedures 
formalize the new process. 
 Lewin's contribution to the DNP Capstone Research Project. Health care providers at 
the study site conducted SPT using the Duotip device and prick technique for over 25 years. 
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Within the department, a single Certified Nursing Assistant conducted a majority of the 
procedures ordered by the physician specialists for the pediatric patients. Over the last two years, 
additional staff members were trained using the twist technique. The health care providers 
expressed concern that results had increased variability when using the twist technique- more 
specifically a higher incidence of erythema and increased false positive and false negative 
results. Lack of confidence in results was further accentuated when multiple trained operators 
conducted the SPT on the highly allergic pediatric patients. 
 The first step in Lewin's Change Theory was to change the status quo. This DNP 
Capstone Research Project aimed to set a new goal and identify a single device and technique to 
standardize the SPT procedure at the facility. This step required unfreezing the current mindset 
by providing a feasible research opportunity, actively listening to the healthcare providers' 
concerns, and allowing input for possible device options. Literature reviews and conversations 
with manufacturers provided a third technique to investigate the Quintip puncture technique. 
 Movement was the second step in Lewin's Change Theory. This step included 
implementing the study, enrolling participants and collecting data for analysis. The author 
worked closely with the healthcare providers, operators, and other support members to discuss 
daily activities and reassess goals dependent on data collected. 
 The last step in Lewin's Change Theory was freezing the change once the new goal was 
attained. Communication of results, training, and educating the healthcare team were mandatory 
to solidify the new process. Updating the current policies and procedures with the new 
information reinforced that positive change occurred. 
 Lewin's Change Theory identified the necessary steps to define the status quo and the 
steps to achieve a new goal through change in practice through evidence-based research. Change 
12 
 
 
 
was easier to accept when team members were involved in every aspect of the change process, 
objectives were clear, and roles defined. Because the three steps of the Change Theory were 
followed sequentially with buy in from the team members, positive change occurred.  
Research Study Objectives 
Study Research Question in PICO Format 
 The PICO (Population, Intervention, Comparison, Outcome) research question that 
served as the focus of the study was defined in Table 1. 
Table 1.  PICO Question 
P Population of Interest Among children ages 1 year to 16 years receiving skin 
prick testing for diagnosis and treatment of their 
allergic disease, 
I Intervention of Interest does the Quintip device puncture technique or Duotip 
device twist technique 
C Comparison of Interest compare to the Duotip prick technique 
O Outcome of Interest decrease variability and increase reproducibility of 
results when conducted by multiple operators? 
           
Study Hypotheses  
    The following hypotheses were tested in this study:  
1. Each of the three SPT techniques- Quintip device puncture technique, Duotip device 
twist technique, and the Duotip prick technique- produce a positive wheal > 3mm to the 
positive control of histamine on the back of the pediatric research participant. 
2. Variability in SPT results was greatest using the Duotip prick technique among multiple 
operators. 
3. Variability in SPT results was the least using the Quintip device puncture technique, 
regardless of operator change. 
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4. The Quintip puncture technique was highly reproducible as compared to the Duotip prick 
and twist techniques. 
Definitions of Study Variables 
1. Quintip Device- Manufactured by Hollister-Stier Laboratories in Spokane, Washington 
and previously reported by the research of Carr et al., (2005) to have low variability in 
results and high sensitivity and specificity. 
2. Duotip Device- Manufactured by Lincoln Diagnostics in Decatur, Illinois and previous 
research conducted by Corder, W., Hogan, M., and Wilson, N. (1996) revealed that the 
bifurcated needle of the Duotip-Test device using the prick/lift technique had 
significantly smaller histamine wheal and erythema responses than Duotip-Test twist 
techniques (P < .05). The Duotip twist technique produced significantly larger wheals 
(mean 1.1 mm, P < .001) to saline than the prick/lift technique.  
3. Concomitant Medications- normal therapeutic doses may suppress SPT results and alter 
variability. 
4. Allergen Extract- can contain proteins that can induce allergic symptoms with exposure. 
The end product is a complex mixture of the diluents or solvents, additives, preservatives, 
and other components of the raw material that survive the manufacturing process. The 
extract must be used before the expiration date or variation in expected SPT results can 
occur. 
5. Storage of Extracts- should be stored at 4° C to reduce the rate of potency. Extracts 
beyond the expiration date should to be discarded. Expired extracts could lead to a 
variation in SPT results. 
6. Distance of Placement on Body Surface- between two SPT should be > 3 cm to avoid 
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false positive reactions due to direct contamination of a nearby test or secondary to an 
axon reflex (Nelson, H.S., 1997). 
7. Dermatographism- is a skin condition also known as skin writing that causes the skin to 
redden when lightly scratched and develop a raised wheal similar to hives. 
8. False Positive Result- Operator presses the instrument too hard against the skin, causing 
erythema from technique versus true allergic response to antigen, causing a false positive 
SPT result (Carr, W. et al., 2005).  
9. False Negative Result- Operator may not press the SPT instrument hard enough against 
the skin so the antigen cannot penetrate the epidermis, resulting in a false negative SPT 
result.  
10. Skin Prick Test Sites Marking- Sites should be marked with washable blue markers to 
identify placement of solutions and pricks should be made immediately adjacent to the 
marks to avoid confusion between solutions. 
Research Methods and Procedures 
Description of Research Design 
    This Doctor of Nursing Capstone Research Project was a prospective, double-blind 
clinical trial using a convenience sample in which pediatric research participants underwent SPT 
in a single session, with a single operator using the Duotip twist and Quintip puncture techniques 
as compared to the Duotip prick/lift technique. Each device was tested on the back and included 
two histamine solutions (10 mg/mL; Hollister-Stier, Spokane, Wash) and two glycerol-saline 
solutions (Hollister-Stier), in a vertical column and spaced at least 3 cm apart.  
 To maintain objectivity, the operator who performed the SPT on the back, was blinded to 
the contents of the test solutions of histamine or saline (Carr et al., 2005). An additional operator, 
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who was not present in the room during solution placement and SPT procedure, recorded the 
results at 15 minutes post procedure. This operator was blinded to the device used at each test 
site, as well as the specific solution tested on the back of each pediatric research participant.  
 All SPT were performed using histamine solutions (10 mg/mL; Hollister-Stier, Spokane, 
Washington) as the positive solution and glycerol-saline solutions (Hollister-Stier) as the 
negative control to compare variability of the SPT size. 
Identification of the Population and Sample Selection 
 All patients followed at the study site, who met the entry criteria, were offered enrollment 
into this study. It was estimated that 50 patients were seen weekly, requiring the SPT procedure 
as a part of their clinical treatment activities.  Of the known patients, approximately 20 eligible 
patients were identified each week. 
 The small population of 600 children was seen at the facility during the study enrollment 
period. A total sample size of 68 pediatric research participants was enrolled into this study. 
Each participant received 12 SPT on his or her back body surface, which were used to determine 
variability and reproducibility of the three techniques. Research participant served as his or her 
own control and were tested using a blinded tray filled with two histamine and two saline 
solutions for each technique and device used by a single trained operator. 
 Power analysis to determine sample size. A sample size of 68 pediatric research 
participants was calculated to achieve a 95% power or sensitivity to detect differences in 
standard deviation between the two devices and three techniques (Faino, 2013). 
Parameters that went into calculation included: 
 
 Alpha= 0.05 
 Standard Deviation (Quintip, back)= 0.95 
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 Standard Deviation (Greer Pick, back) = 1.81  (Values from Werther et al., 2012)  
Note: Greer Pick is a surrogate to Duotip twist  
N1 verses Power S1 = 1.8100, S2 = 0.9500, Alpha = 0.05, N2 = N1, 2-sided F Test 
Table 2. Power Analysis of Variances 
 
 
 Power analysis of variances. Numeric: Results when H0: S1 = S2 verses Ha: S1 ≠ S2 
Power N1 N2 S1 S2 Alpha Beta 
0.990636 47 47 1.8100 0.9500 0.050000 0.009364 
0.953888 34 34 1.8100 0.9500 0.050000 0.046112 
0.907893 28 28 1.8100 0.9500 0.050000 0.092107 
0.856790 24 24 1.8100 0.9500 0.050000 0.143210 
0.803054 21 21 1.8100 0.9500 0.050000 0.196946 
0.758083 19 19 1.8100 0.9500 0.050000 0.241917 
0.704637 17 17 1.8100 0.9500 0.050000 0.295363 
 
*This test was assuming independence between the groups and was likely an overestimation 
of the total number of patients needed. Thus additional participants were not needed to cover for 
unusable data (Faino, 2013). 
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 Population/sampling parameters. All current and newly diagnosed patients (based on 
medical history and/or community physicians referral information) with suspected food, drug or 
environmental allergies, were offered enrollment into this DNP Capstone Research Project.  
The Inclusion Criteria: 
1. Children with suspected food, drug, or environmental allergies - ages 1 to 16 years old  
2. Both genders, all races and ethnic groups 
3. English speaking only 
4. Medications, included but not limited to antihistamines, withheld for appropriate time 
period as per hospital protocol 
The Exclusion Criteria:  
1. Inability to comply with SPT procedure 
2. Failure of a family/patient to sign the informed consent document or the HIPAA medical 
record release form 
 Recruitment plan. In order to maximize recruitment of participants with suspected food, 
drug, or environmental allergies, two recruitment strategies were used: 
1. Current and future Clinical Site Patients - The principal investigator discussed the study 
design, benefits and possible risks with the family.  Printed information about the study 
and the consent form were given to the family.  The IRB-approved consent form included 
the purpose of the trial, the responsible parties and investigator, potential benefits, risks 
of participation, the right to refuse to be in the study, the right to withdraw from the study 
under no penalty, contact numbers and information about the responsibility for injury and 
payment for medical care.  If the family consented to participant in the study, written 
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informed consent was obtained from the parents or guardians and case report forms were 
completed. 
2. Advertising Strategy for Voluntary Enrollment- To increase the sample size, several steps 
were taken to add to the recruitment of study participants. A periodic IRB-approved 
announcement of the objectives of the DNP Capstone Research Project was made on the 
Pediatric Department Bulletin Board with a request for referral of patients. In addition, 
the principal investigator posted IRB approved notices on the Pediatric Clinic and 
Pediatric Care Unit bulletin boards to announce the new study and provided contact 
information for interested families or patients.  
 Study enrollment. During the six-month duration of this study, the plan was to enroll 68 
patients at the study site. The ethnicity and racial categories of the participants are outlined in 
Table 3.  
Table 3. Planned Enrollment Table. 
Ethnic Categories Gender 
Females Males Total 
Hispanic or Latino 6 7 13 
Not Hispanic or Latino 27 28 55 
Ethnic Categories: Total of All 
Participants 
33 35 68 
  
Racial Categories    
American Indian/Alaska Native 1 1 2 
Asian 1 1 2 
Native Hawaiian or Other Pacific 
Islander 
0 0 0 
Black or African American 3 4 7 
White 28 29  
Racial Categories: Total of All 
Participants 
33 35 68 
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Setting Description 
 Participants were recruited from patients evaluated, referred, and followed at the study 
site in Denver, Colorado.  The principal investigator identified the parent(s) or guardian(s) 
during Pediatric Clinic visits or during inpatient, day patient admissions, or triage visits within 
the Pediatric Care Unit.  The principal investigator discussed the study design, benefits and 
possible risks with the family. Printed information about the study and a copy of the consent 
form were given to the family.  
Stakeholders and Project Team 
 Mentor. Dr. Erwin Gelfand, Chairman Department of Pediatrics, provided mentorship 
and guidance to the author and principal investigator of this DNP Capstone Research Project. Dr. 
Gelfand is internationally recognized as reporting of his research endeavors, publications and 
leadership positions posted on the facility website (http://www.nationaljewish.org/about/people-
search, 2013). 
 Capstone Chair. Dr. Diane Ernst, Associate Professor at Regis University, provided 
education and guidance throughout this DNP Capstone Research Project. Dr. Ernst's clinical 
expertise and certification are centered on community and public health outcomes.  Her research 
activities include nursing-sensitive outcomes  research, health promotion and illness prevention 
in older adults, and research within the  community/public health settings. 
 Medical Director at the study site. Dr. Pia Hauk, Medical Director Department of 
Pediatrics, provided medical assistance as necessary if an adverse event occurred. Dr. Hauk 
oversees all clinical activities within the Department of Pediatrics including the areas of the 
Pediatric Clinic, Triage, and Pediatric Care Unit. 
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 Additional advisory team members. To complete the DNP Capstone Research Project, 
active collaboration occurred with Anna Faino, Biostatistician at the facility. Following the 
departure of Ms. Faino from the institution, Dr. Ronina Covar, Associate Professor in the 
Division of Pediatric Allergy and Clinical Immunology and Director of The Cohen Family 
Asthma Institute, Head of Pediatric Clinical Pharmacology, and Biostatistician assisted in the 
statistical validation and analysis of the study. Pediatric Physician Specialists from the facility, 
whom raised the initial concerns regarding concern of operator variability, were available during 
the enrollment period. Ms. Kelly Buller, RN and SPT preceptor, and Ms. Suseth Figueroa, expert 
SPT operator, were regularly consulted regarding SPT technique, education, and training. 
 The facility's mission, vision, and organizational structure supported the educational 
endeavor and provided the necessary physical and financial support to complete the project. Dr. 
Erwin Gelfand and other members of the advisory team are experts in their field and provided 
necessary guidance to the overall success of the project.  
 Community partnerships. In order for this project to be successful, community efforts 
from different teams were developed. For example, the DNP Capstone Research Project involved 
two separate device manufacturers and the Institutional Review Boards at Regis University and 
the study site. The two Institutional Review Boards worked together to ensure the safety of 
research participants and allowed medical research to proceed in an ethical manner without 
either intentional or unintentional abuses of power or errors 
 Interdisciplinary collaboration. Conducting research to identify a single SPT device 
and technique required interdisciplinary collaboration. Adult and pediatric health care teams 
relied on accurate results to define initial diagnoses and ongoing treatment plans for allergic 
patients. Support staff and SPT operators were able to identify appropriate patients for the 
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project.  The principal investigator collaborated fully with the attending physicians to approach 
potential patients for participation. At the conclusion of the study, results were shared with all 
departments and policy and procedure were amended to reflect the superior device and 
technique. Communication was extensive with all health care team members at the table for 
discussion of results. 
Protection of Human Rights Procedures 
 Institutional review boards. The research protocol, consent, assent, and other regulatory 
documents were reviewed and approved by the facility's Institutional Review Board and Regis 
University Institutional Review Board. All pediatric research participants enrolled into the study 
voluntarily agreed to participate and gave written informed consent by parent or legal guardian 
and assent from child research participant. 
 Regis University institutional review board. verified and approved all research 
activities involving human research. The board met monthly to verify exempt studies, determine 
and review expedited studies, and conduct formal meetings for studies requiring full review. 
Even though this study involved a vulnerable population, the research was minimal risk and 
qualified for expedited review. Two designated Regis University IRB members reviewed the 
regulatory packet and granted approval. 
 Facility's institutional review board. was consulted during the development of the 
DNP Capstone Research Project and determined that the protocol met the requirements for 
expedited review. 
 As described on the facility's website (2013), "Expedited review is an option when 
the research activity will expose participants to no more than minimal risk and when the 
proposed study falls into a category described in the federal regulations. Because the risks of 
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participating in the research are no more than minimal, the regulations allow the study to be 
reviewed by the IRB Chairperson or an experienced IRB member". 
 Procedure for requesting an expedited review of a new protocol. Author and 
principal investigator applied for expedited review and completed the appropriate submission 
requirements found on their website There were no submission deadlines for expedited 
review. Once the regulatory packet was logged into the system, a Primary Reviewer was 
assigned to the protocol and communicated directly with the principal investigator or IRB 
contact person. Once all stipulations had been adequately addressed, the protocol was 
approved and the principal investigator was notified. An expedited review required two to 
three weeks, but it is dependent upon the availability of the Primary Reviewer.  
 Informed consent plan. All potential participants were identified by the principal 
investigator and those meeting the inclusion/exclusion criteria were given the opportunity to 
participate. Parents/guardians/ participants were given the consent/assent forms to review and 
ask questions about the study. Parents/guardians/participants were asked to summarize in 
their own words what participation in this research study involved and that they are 
comfortable with the risks and benefits of participating in the research study. Any additional 
questions they had were answered prior to signing the consent/assent. Once the 
consent/assent form was signed, a copy was provided to the parent/guardian/participant. All 
participants were consented by the Principal Investigator who had appropriate training 
regarding human participant protection and HIPAA compliance, as established by the local 
institutional regulatory requirements.  Only English speaking participants were able to 
participate in the study. 
 Special consent/assent plan. Spanish only speaking population were excluded from 
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this study.  Children 7 years of age and greater were asked to sign assent after the protocol 
was explained by the principal investigator. 
 Incentives or rewards offered for participation. Patients, parents or guardians did not 
receive reimbursement for their participation in this research study. Patients were not charged for 
their participation in this study. 
 Potential risks to participants. There were minimal physical and psychological risks 
from being in this study. Brief minimal localized site pain was associated with the SPT 
procedure and resolved immediately without treatment once the prick was completed. No 
additional treatment was necessary to resolve pain. 
 Alternative treatments considered. Patients could have elected to not participate in the 
study and receive SPT as a part of their routine clinical care.  
 Plan to protect participants/mitigate risks. The study anticipated no excessive risks to 
the patients, except the possible pain associated with the SPT. Once the procedure was 
completed and in the 15-minute wait period, a small fan was directed to the back area to 
minimize any discomfort if requested.  
 Criteria for removal from study. Participants were seen one time immediately 
following enrollment into the study. The participants' parents or guardians could request that the 
patient be removed from the study at any time.  In addition, the investigator could withdraw a 
participant from the study if she determined that it was in the participant’s best interests. 
Withdrawal from the study would not impact the study participant’s future medical care.  
 Potential health benefits to participants. The pediatric research participants did not 
directly benefit from participation in this research, but in the future, other children needing to 
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undergo the SPT procedure may benefit from new information that may lead to better medical 
care. 
 Importance of the knowledge gained from this research. was to better understand of 
the SPT technique and devices used, and lead to improvements in diagnoses and treatments for 
food, drug and environmental allergies. This study was designed to identify a single device and 
technique that could be used at the facility to reduce variability, increase reliability, and 
standardize the procedure using a single technique and device within the institution. 
Description of the Study Intervention/ Protocol 
 This prospective, double-blind research study offered comparison in the performance of 
the Duotip twist and Quintip puncture techniques as compared to the Duotip prick/lift technique. 
The purpose of this study was to determine the best SPT technique and device that could be used 
efficiently and effectively to identify and treat severe allergies to drugs, foods and environmental 
allergens. This inexpensive test has the potential to yield enormous results at a single visit and 
dictate lifesaving treatment, which is patient specific. 
 This DNP Clinical Research Project was performed under Good Clinical Practice 
guidelines (FDA, 2013), which enforced tight rules on ethical aspects for human research. Good 
Clinical Practice guidelines aim to ensure that studies are scientifically valid, necessary 
procedure and tests are safely performed, and all research activities are accurately documented. 
In addition, the Good Clinical Practice Guidelines provide information about subject protection, 
roles and responsibilities of the research team and participants, and study oversight (FDA, 2013). 
Four Certified Nursing Assistants and two Registered Nurses involved in this DNP Clinical 
Research Project completed their CITI training and other regulatory requirements as required by 
the local Institutional Review Board. Medical liaisons from Lincoln Diagnostics, Inc. and 
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Hollister Stier, manufacturers of the devices, provided educational training sessions on the 
Quintip punch technique and the Duotip twist technique before first subject was enrolled into the 
study. Operators performed all SPT on the pediatric research participants, and another trained 
SPT operator immediately read all of the results at a specific time interval and documented the 
results in the SPT test form.  
 Research intervention. Each subject underwent 12 SPT during a single session with a 
single operator using the Duotip twist and Quintip puncture techniques as compared to the 
Duotip prick/lift technique. Each technique and device were tested on the back of the pediatric 
participant, using two tests of the histamine (10 mg/mL; Hollister-Stier, Spokane, Wash) positive 
control solutions and two tests of the glycerol-saline (Hollister-Stier) negative control solutions 
during the session. At the conclusion, a mean result was determined for each test of the single 
use devices, and from this, intradevice variability was defined. Single device test sites were 
spaced at least 3 cm apart, in three row of four SPT, and marked with a pen on the back to 
properly identify test locations.  
    To maintain objectivity, the operators who performed the SPT on the back were blinded 
to the contents of the test solution of histamine or saline control solutions. An additional 
operator, who were not be present in the room during application and testing of solutions and 
controls, recorded the results. This operator was blinded to the devices used as well as to the 
particular solution placements on the back of the research participant. The largest diameter was 
measured first using a clear ruler, followed by the perpendicular diameter, passing through the 
middle of the wheal and documented. The measurement was repeated on the surrounding 
erythema or flare response using the same technique. Wheals greater than 3 mm in diameter were 
considered positive at the histamine sites and indicative of clinical allergic response. 
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Discussion of Measurement Techniques/ Instruments 
 Devices. Single headed devices were evaluated in the DNP Capstone Research Project 
including the Duotip (Lincoln Diagnostics) used for the prick and twist techniques and the 
Quintip (Hollister-Stier) used for the punch technique. 
 Skin prick testing. All testing was performed on the back. The wheal and flare results 
were recorded at 15 minutes post placement by obtaining the longest orthogonal diameters. Mean 
diameters were used for statistical analyses. Positive test solution was 10-mg/mL histamine 
(Hollister-Stier), with standard glycerol saline (Hollister-Stier) used as the negative solution. The 
controls were tested twice in each row to ensure reactivity and variability for each device. The 
different SPT studied in this protocol share clinical responsibilities for the diagnosis and 
treatment of pediatric allergies.  In the following, the current state of knowledge about each 
technique was summarized and current scientific and clinical challenges were outlined. 
1. Duotip prick and twist techniques- Lincoln Diagnostics.   Duotip-Test® is the most 
affordable one-at-a-time SPT on the market (www.lincolndiagnostics.com, 2013). 
 As reported on the Lincoln Diagnostic website (2013), the Duotip is: 
 Highly sensitive and specific 
 Well-defined, easy-to-read reactions 
 Excellent patient acceptance 
 Rapid, convenient, and easily learned technique as reported by manufacturer 
 Used via modified prick or rotation (twist) 
 Lowest cost one-at-a-time procedure per manufacturer report 
 Compact system requires little storage and disposal space 
 OSHA Compliant for blood borne pathogens and needle stick prevention 
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2. Quintip punch technique- Hollister-Stier. Quintip is a SPT device manufactured by 
Hollister-Stier Laboratories, Spokane Washington. The Quintip is designed to perform as 
reported on their website (http://www.hsallergy.com): 
  to apply allergen extract using a puncture technique 
 Stainless steel lancet tip that protrudes from the molded plastic grip, enough to give the 
proper testing grip 
 Is to be used once and discarded in appropriate sharp container 
 Can be stored in the extract-filled trays when not in use or in shipping package 
 With the Quintip perpendicular to the skin, tester presses down on the skin with medium 
pressure without lifting the device from the skin. Remove by lifting vertically and discard 
in approved sharps container. A small visible circle should remain at the test site 
indicating that the correct amount of pressure was applied 
 The visibility of the circles will vary between patients according to thickness, fragility, 
and pigmentation of the patient's skin 
Plan for Data Collection 
 Data collection and study visit schedule. This study involved collection of clinical 
information, medical history, medication history, brief physical findings, and SPT.  
The following data was collected on study participants at enrollment and during the single study 
visit.  
Enrollment/Study Visit 1  
1. Demographics: age at entry, date of birth, gender, race and ethnicity 
2. Clinical Presentation: brief history of allergic symptoms, signs, age at onset, and initial 
interventions 
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3. Current Medications and Diet History 
4. Brief Physical examination: Measurements: vital signs; Appearance: skin assessment  
5. Skin Prick Tests: using Duotip prick and twist technique and Quintip punch technique 
Table 4. Study Visit 
 
The single study visit included the following: 
 
EVALUATION VISIT 1 
Informed Consent X 
Eligibility X 
Medical History X 
Medication History X 
Brief Physical Examination X 
Skin Prick Tests X 
Discharge X 
 
Plan for Data/ Statistical Analysis 
 Wheal results were analyzed using repeated-measures ANOVA (Analysis of Variance) 
with the limited factors of back body site of 68 pediatric research participants and device. When 
calculating sensitivity and specificity, a positive test had a wheal of 3 mm or greater, and the 
negative test had a wheal of less than 3 mm.  If the histamine results were less than 3 mm, the 
result was considered a false negative. Wheals greater than 3 mm in diameter were considered 
positive and indicative of clinical allergic response. 
 Skin prick test results were recorded using the largest diameter (D1) measured first using 
a clear ruler, followed by the perpendicular diameter (D2), and passing through the middle of the 
wheal. The measurement was repeated on the surrounding erythema or flare response using the 
same technique. The mean diameter (MD) was calculated using the formula:  
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MD = (D1 + D2)/2. 
 Sensitivity of each technique was calculated using the true positive result of 3 mm for the 
mean diameter (MD) of each wheal. Similar to the analyses of Masse et al. (2011) research study 
and Carr et al., (2005) research study, sensitivity was calculated by dividing true positive results 
by the sum of true positive and false negative results. Specificity of each technique was 
calculated by using the true negative results divided by the sum of the true negative and false 
positive results. The positive predictive value (PPV) is the proportion of subjects that are actually 
positive, among those that are predicted to be positive. The negative predictive value (NPV) is 
the proportion of subjects that are actually non-positive, among those that are predicted to be 
non-positive, and was calculated using the formula. 
 Interpatient reproducibility (using the same technique on multiple patients) and 
intrapatient reproducibility (same patient but using different techniques) were researched in this 
study. To assess intrapatient (same patient) reproducibility, the coefficient of variation (CV) 
between the mean diameters (MD) of the results using the same technique were calculated using 
the following formula (Masse et al., 2011): 
CV intrapatient = SD intrapatient / μ intrapatient 
where the SD and μ are the standard deviation and the MD of the results. 
 Interpatient (different patient, same technique) variation of wheal size comparing 
different patients using same technique were calculated using the following formula (Masse et 
al., 2011): 
CV interpatient = SD interpatient / μ interpatient 
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The coefficient of variation represented the ratio of the standard deviation to the mean and was 
an essential statistical measurement used to compare the degrees of variation from one device 
and technique to another regardless how different the means were to one another. 
 The formal statistical method to measure the variability in wheal size for each of the three 
techniques was performed using a single multilevel model. As noted by Werther et al., (2012), 
this allowed for "correlations between observations taken by the same operator and carried out 
on the same receiver using random effects". The model separated the variability in SPT 
measurements into 3 components: variability between operators, variability between receivers, 
and variability within operators and receivers". 
With the assistance from the Dr. Ronina Covar at the facility, sensitivity and specificity 
were calculated and variation defined between SPT techniques and devices.  
Results 
   Study hypotheses.  The following hypotheses were tested in this study:  
1. Each of the three SPT techniques- Quintip device puncture technique, Duotip device 
twist technique, and the Duotip prick technique- produce a positive wheal > 3mm to the 
positive control of histamine on the back of the pediatric research participant. 
2. Variability in SPT results was greatest using the Duotip prick technique among multiple 
operators. 
3. Variability in SPT results was the least using the Quintip device puncture technique, 
regardless of operator change. 
4. The Quintip puncture technique was highly reproducible as compared to the Duotip prick 
and twist techniques. 
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A total of 68 children with a mean age of nine years (range: 4-16 years) participated in 
the study (Figure 1).  Thirty-nine males and 29 females enrolled with their specific race and 
ethnicity demographics defined in Figure 2 and Figure 3.  
 
Figure 1. Age of subjects at time of enrollment 
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Figure 2. Race and ethnicity results of males enrolled 
 
 
Figure 3. Race and ethnicity results of females enrolled 
   
 
Black, Hispanic, 
Male
8% Black, Non-
Hispanic, Male
10%
Caucasian, 
Hispanic, Male
41%
Caucasian, Non-
Hispanic, Male
38%
Indian, Non-
Hispanic Male
3%
Total Males Enrolled
Black, Hispanic, 
Female
7%
Black, Non-
Hispanic,  Female
4%
Caucasian, 
Hispanic,  
Female
41%
Caucasian, Non-
Hispanic,  Female
45%
Indian, Non-
Hispanic  Female
3%
Total Females Enrolled
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  Study Hypothesis #1:  Each of the three SPT techniques- Quintip device puncture 
technique, Duotip device twist technique, and the Duotip prick technique- produce a 
positive wheal > 3mm to the positive control of histamine on the back of the pediatric 
research participant. 
  Results revealed that each of the three SPT techniques- Quintip device puncture 
technique, Duotip device twist technique, and the Duotip prick technique- produced positive 
wheals > 3mm to the positive control of histamine on the back of the pediatric research 
participants, supporting the research hypothesis (Table 5). 
  Each subject had at least one True Positive (TP) wheal defined as > 3 mm in mean 
diameter and one True Negative (TN) wheal < 3mm in mean diameter. 
Each of the three SPT techniques- Quintip device puncture technique, Duotip device 
twist technique, and the Duotip prick technique- produce a positive wheal > 3mm.   
Table 5. Median Wheal Size 
Technique Minimum 10% 25% Median 75% 90% Maximum  
Prick/Lift 0  2.35 4 5  6.5 7.5 12  
Punch  0  2 4 5  5 6.5 8  
Twist  0  4 5 6.5  7.5 8.5 14.5  
 
Using a non-parametric statistical method, Wilcoxon test, to rank each test in numerical 
order against each test and then against each technique using the median value in 4 different 
quartiles, the analysis revealed that all three techniques produced positive wheals when exposed 
to the positive antigen of histamine. Each subject had at least one True Positive (TP) wheal 
34 
 
 
 
defined as > 3 mm in mean diameter and one True Negative (TN) wheal < 3mm in mean 
diameter.  
Mean diameter of wheals, small red bumps developed on the skin where the allergens 
were placed, were recorded at precisely 15 minutes later by a second trained operator. For this 
study, the size of the wheals only represented positive skin prick tests and did not indicate the 
severity of the symptoms or sensitivity to the histamine (true positive) or saline (false positive).  
Table 6. Sensitivity and Specificity 
Technique/device TP    FN  Sensitivity %  Specificity %   
Quintip Punch  117    19  86%   96.3%   
Duotip Prick/Lift 121    15  88.9%   97%   
Duotip Twist  132     4  97%   83.8% 
 
Comparing results between the three techniques and two devices, the twist method was 
most sensitive (97%) as compared to the punch technique (86%) and prick/lift technique (89%). 
Only 2.8% of those tested using the twist technique produced false negative responses to 
histamine as compared to 14% (Quintip punch) and 11.1% (Duotip prick/lift). 
The SPT with 100% sensitivity correctly identifies all subjects with the positive 
histamine response. The overall SPT sensitivity detected 91% of subjects with a true positive 
response to histamine and a 9% of false negative responses to histamine (false negative). 
Sensitivity is paramount when the SPT is used to make treatment decisions, open diets, and 
allow exposure to allergens. 
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Table 7. Contingency Analysis of Positive (H) vs. Negative (S) 
Technique Test    ChiSquare   Prob>ChiSquare 
PrickLift Pearson  202.634   <.0001 
Punch  Pearson  186.446   <.0001 
Twist  Pearson  181.114   <.0001 
Technique  FN  FP  TN  TP 
PrickLift  15  4  132  121 
Punch   19  5  131  117 
Twist   4  22  114  132 
Number Test    ChiSquare   Prob>ChiSquare 
816  Pearson  31.940    <.0001 
 
Measures of Association-  Pearson Test ChiSquare was used for this study as defined in 
Table 7. Since the rows and columns in a table were completely independent of each other, the 
entries in the table (distribution of mass) were reproduced from the row and column totals alone, 
or row and column comparison analysis. The sums of the frequencies across the columns must be 
equal to the row totals, and the sums across the rows equal to the column totals. The results for 
this DNP study were found to be statistically significant as represented by the p value <.0001. 
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Study Hypothesis #2: Variability in SPT results was greatest using the Duotip prick 
technique among multiple operators. 
Variability in the SPT results to histamine was greatest using the Duotip prick technique 
among multiple operators. 
Table 8. Variability in SPT to Histamine 
HISTAMINE      
Technique/Device   Number Mean  Standard            Co-efficient  
                            Deviation           of Variation 
  
Prick/Lift  136  4.95221 2.17722          44.0   
Punch   136  4.35662 1.74686                 40.1   
Twist   136  6.46750 2.36714          36.6  
 
The one-way AVONA analysis using parametric measurements and a p value of less than 
0.0001 suggested that the Duotip prick lift method was highest as compared to the other methods 
as defined by the Co-efficient of Variation, or the variation in the ability to repeat the test in 
same tests in patients. 
Duotip twist method was highly sensitive as noted on the previous slide (97%) even 
though the mean (6.5) and standard deviation are largest (2.36714). Results indicate the twist 
tests are highly reproducible as noted with the lowest coefficient of variation (36.6).  
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Study Hypothesis #3: Variability in SPT results was the least using the Quintip 
device puncture technique, regardless of operator change. 
Variability in the SPT results to histamine was least using the Duotip twist technique 
among multiple operators (Table 9). 
Table 9. Variability in SPT- Mean, Median, and CV 
HISTAMINE      
Technique/Device   Median                       Mean          Co-efficient  
              of Variation 
Prick/Lift  5.0 (4.0, 6.5)     5.0±2.2         44.0   
Punch   5.0 (4.0, 5.0)     4.4±1.7         40.1   
Twist   6.5 (5.0, 7.5)     6.5±2.4         36.6   
 
Variability in SPT results was the least using the Quintip device puncture technique, 
regardless of operator change. 
Using the Wilcoxon test to conduct non-parametric analysis using the median data and 
ANOVA test to conduct parametric analysis using the mean data, resulted in the same message 
that the twist method using the Duotip device had the least variation in results. 
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Research Hypothesis #4: The Quintip puncture technique was highly reproducible 
as compared to the Duotip prick and twist techniques. 
Table 10. Reproducibility of Techniques 
HISTAMINE      
Technique/ Median           Mean          CV     TP          FN        Sensitivity    Specificity        
Device 
Prick/Lift 5.0 (4.0, 6.5)    5.0±2.      44.0 121         15  89%   97%  
Punch  5.0 (4.0, 5.0)    4.4±1.       40.1 117        19     86%   97%  
Twist  6.5 (5.0, 7.5)    6.5±2.       36.6 132           4  97%   84% 
 
The Quintip puncture technique was highly reproducible as compared to the Duotip prick 
and twist techniques as defined by the differences in wheal means and standard deviations of the 
data between the different techniques. The one-way AVONA analysis using parametric 
measurements and a p value of less than 0.0001 further suggested that the Duotip twist method 
was highly sensitive and able to provide true positive results while limiting false negative SPT 
results when conducted on the back of children.  
The Coefficient of variation, or the variation in the ability to repeat the same test in 
patient, is the lowest with the twist, using histamine and saline, as compared to the other two 
techniques (Table 10). 
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Table 11. Mean Wheal Diameter 
 
The median wheal diameter is largest with the twist (6.5) as compared to the prick/lift 
and punch (5). In addition the twist has the largest histamine wheal (14.5) when compared to the 
prick/lift (12) and punch (8). This may be reflective of the “twisting” or traumatic nature of the 
technique. 
Another way to look at the data included comparing the two histamines within a given 
column and comparing the overall pairs to one another. The statistical differences in matched 
pairs within columns were identified and compared to all matched pairs in total to identify the 
mean differences. The Prick Lift had the greatest mean difference in histamine measurements 
between H1 and H2 as reflected by the P value of 0.0387.  
The twist technique was the least variable and most reproducible with the mean 
difference of -0.082 between H1 and H2. 
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Table 12. Agreement between H1 and H2 
 
Agreement between H1 and H2 using continuous variables 
Technique Test   Result   Statistical Significance 
PrickLift H2   5.213 
PrickLift H1   4.691 
Prick Lift Mean Difference 0.522   0.0387 
Punch  H2   4.125 
Punch  H1   4.588 
Punch  Mean Difference         -0.463   0.0878 
Twist  H2   6.426 
Twist  H1   6.508 
Twist  Mean Difference         -0.082    0.7937  
 
 In conclusion, with proper education and training the skin prick test can be used to 
identify and treat severe allergies to drugs, foods and environmental allergens. This inexpensive 
test has the potential the yield enormous results at a single visit and dictate life saving treatment, 
which is patient specific. This prospective, head-to-head comparison of the performance of two 
single use skin test devices using the Duotip twist method and Quintip punch method as 
compared to the Duotip prick/lift method. This study was performed under the best of clinical 
circumstances, with operators trained by representatives of the manufacturers, and who 
performed all skin testing, and another trained skin test operator who read all of the results. We 
found significant differences among all devices to be tested.  
 
41 
 
 
 
Dissemination of Study Results 
 
 Data results were shared once all research participants were enrolled, study visits 
complete and data analyzed. Information was shared internally at the Pediatric Faculty meeting 
and staff meetings within the Pediatric Care Unit and Pediatric Clinic in the study site. 
Implication for Practice and Future Research 
 Interestingly, even though SPT is associated with minimal pain and yielding significant, 
very little research has occurred to verify its reliability or define clinical treatment protocols for 
its use. As new devices and techniques are being produced, continued evaluation of these devices 
will be to be conducted to determine potential for variability and reproducibility among SPT 
operators across all age groups.  
 Following the outcome of this DNP Capstone Research Project, future research 
investigations may include: 
• Food, Environmental, and Medication allergen testing on pediatric patients 
• RAST results correlated to SPT results 
• SPT results correlated to Oral Food Challenges 
• New devices and techniques compared to the outcome of this study 
 Recommendations for on-going skin prick testing. Skin prick testing research must be 
continual and new devices must be assessed before implementation regardless of the age group 
for intended use. With proper education and training, the skin prick test can be used to identify 
and treat severe allergies to drugs, foods and environmental allergens. Overall, skin testing is 
associated with minimal pain, and individual physicians commonly use the test to diagnose and 
treat drug, food and environmental allergies. As new devices and techniques are being produced, 
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continued evaluation of these devices will be to be conducted to determine potential for 
variability and reproducibility among skin test operators. 
 In summary, this Doctor of Nursing Practice (DNP) Clinical Research Project aimed to 
discover knowledge of skin prick test (SPT) technique to enhance diagnosis and treatment of 
potentially life threatening allergies in the pediatric population at National Jewish Health's 
NJ4Kids Program. The results will integrate research, clinical and educational efforts to 
positively impact clinical care through evidence-based research in the pediatric population.     
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Timeframe and Budget/ Resources 
Table 13.  Logic Model for the Doctor of Nursing Practice Clinical Research Project 
Resources- 
Input 
Activities Constraints Outputs Outcomes Impacts 
Funding in 
the form of 
supplies 
supporting 
Capstone 
Research 
Project 
Provide 
immediate 
SPT results 
for allergen 
testing 
Devices and 
allergens are 
eliminated 
Deliver 
prompt 
diagnostic 
results for 
food, drug, 
and 
environmental 
allergens 
Early and 
immediate 
diagnosis of 
allergic 
triggers 
Project 
funded with 
supplies 
through 
August 
2014 
(revised 
December 
2014) 
Research and 
Grant 
infrastructure 
of the facility 
Comprehens
ive grant 
manage-
ment of 
clinical 
research 
study 
including 
regulatory 
and clinical 
research 
activities. 
Delay in 
IRB 
approval 
Adherence to 
grant policy 
and 
procedures as 
mandated by 
local internal 
review board.  
Regulatory 
oversight for 
Participant 
and Principal 
Investigator 
First clinical 
research 
study 
submitted to 
IRB- 
December 
2013 
(Revised 
March 
2014) 
The facility 
Infrastructure 
Outpatient, 
laboratory 
and 
Pediatric 
Care Unit 
facilities 
Potential 
lack of 
clinical 
space due to 
busy daily 
clinics 
Attend 
scheduled 
research visit 
Increased 
patient 
satisfaction 
by providing 
comprehensi
ve care in 
clinic 
Adequate 
space and 
support 
Immediate 
access to the 
facility for 
validation of 
initial 
diagnosis 
Early 
intervention 
with 
laboratory 
and clinical 
diagnostic 
evaluations 
Allergist 
unavailable 
Validation of 
initial positive 
SP 
Results 
evaluated 
immediately 
and plan 
discussed 
with patient  
Early 
intervention 
and 
treatment 
for 
identified 
allergies 
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Study Timeline 
 Planned duration of the entire study. It was anticipated that enrollment would begin in 
March 2014 and conclude within two months. Data was analyzed and prepared for submission 
for publication in Winter 2014. 
 CITI Training for SPT Operators- December 2013 
 Regis DNP Proposal Presentation- March 2015 
 IRB submission to the facility's Institutional Review Board- March 2014 
 IRB submission to Regis University Review Boards- May 2014 
 Medical Liaison Training Presentations- January 2014 
 Research Protocol Presentation to the facility Faculty and Staff- June 2014 
 Enrollment Period- August-October 2014 
 Data Analysis- November-2014 -August 2015 
 Final Presentation- September 2015 
Duration of participation for each participant. Each research participant’s 
involvement in this research study occurred on a single day with the study visit lasting less than 
two hours. This included the informed consent discussion and SPT procedure. 
Study Budget/ Resources 
 In 2012, the State of Colorado elected to not reimburse for the SPT and instead would 
only provide financial coverage for oral food challenges.  Specialists from the facility and other 
allergy practices pleaded with the State Health Department and state lawmakers to reconsider, 
arguing the oral food challenges place the patients at extreme risk that are unknown beforehand 
if SPT is not performed ahead of time.  The State of Colorado reversed their decision and now 
reimburse for the tests (Gelfand, 2013). Most private insurance companies and health 
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maintenance organizations pay for this service and prefer to limit oral food challenges until 
deemed safe to do so. 
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Appendix A 
 
SWOT ANALYSIS 
 
 
STRENGTHS                                                                          WEAKNESSES               WEAKNESSES 
1. What are your strengths?                                      1. What are your weaknesses? 
2. What do you do better than others?                      2. What do your competitors do    
                                                                                      better than you?         
3. What unique capabilities and                                3. What can you improve given 
    resources do you possess?                                        current situation? 
4. What do others perceive as your strengths?          4. What to others perceive as        
            your weaknesses?      
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
• Large institution 
• Multiple divisions covering all 
disciplines and facets to make the 
organization work - 
• Supportive of hospital-wide quality 
improvement 
• Expertise in multiple specialty 
areas/world-renowned healthcare 
providers 
• Advanced technological 
infrastructure- EMR 
• Regional coverage through network 
of care sites 
• Regional partnerships with other 
healthcare networks – broadened 
market share 
• Allow customers of all payer mixes  
• Magnet designated 
•  Small tertiary facility 
• Specialty hospital focusing on 
pulomonary, asthma and allergy, and 
immunology medicine 
• World reknown xpertise in several 
specialty areas 
• Main hospital and several offsite 
clinics 
• Local partnerships with adult 
intensive care units 
• No patient  will be turned away 
regrdless of financial status 
• Significant research experience- 
bench and clinical 
• Seen at the center of "last resort" by 
patients and  referring physicians 
• Patients referred from around the 
world 
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OPPORTUNITIES               THREATS 
1. What trends or conditions may positively             1. What trends or conditions may  
    impact you?                                                               negatively impact you?  
2. What opportunities are available to you?  2. What are your competitors doing   
                      that may impact you? 
       3. Do you have solid financial  
                          support? 
       4. What impact do your         
                      weaknesses have on the threats   
               to you?           
 
  
   • Letter of Intent signed 
with SCL/St. Joseph's 
Hospital as first step of 
a Joint Operating 
Agreement 
• Funded research 
activities 
• Partnerships with local 
and national respected 
academic medical 
facilities 
• Department of 
Medicine has continued 
to attract highly sought 
after physicians 
• Development has had a 
banner year despite the 
national economic 
struggles 
• 48 hour appointments 
within the department 
of pediatrics has 
increased business 13-
16% 
• Competitor growing extremely 
fast  
• Competitor's large workforce 
make standard processes 
difficult to sustain and 
implement 
• Competitor has extremely 
recognizable brand and 
excellent marketing efforts, 
allowing for solid financial 
support from community and 
foundation 
• Competitor seeking to see 
every pediatric medical visit in 
the Rocky Mountain region- 
Huge competition 
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Appendix B 
 
Study Budget 
Full Study Title: Reducing Variability 
Among Multiple Operators Using a 
Single Technique and Device for Skin 
Prick Testing in Children 
   
 Protocol Number: HS 2826    
 Principal Investigator: Elizabeth Esterl 
RN, MS 
   
 Sponsor: PI Initiated. Unfunded    
 Coordinator: Elizabeth Esterl RN, MS 
    Date: February 01, 2014 
    
     Facility IRB and Administrative 
Invoiced Fees         
These fees are to be paid immediately 
upon receipt of invoice.         
Initial Review Fee (subject to change) 
waiver 
submitted  IRB  
Non-
negotiable waived 
Consent - Spanish Translation Fee 
$40.00 per page/ 8 pages total $200.00 Translation 
Non-
negotiable 
Fixed 
Direct 
     These fees are subject to change 
upon notification from the local IRB 
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Protocol Number: HS 2826
Principal Investigator: Elizabeth 
Esterl RN, MS
Sponsor: PI Initiated. Unfunded
This is a 12 month budget and 
pricing wil be increase 7% each year 
thereafter based on the date of the 
contract.
[ ] Budget accepted with Non-
Refundable Start up Fees and 
Alacarte Menu of Fee for Services Comments
Cost per 
Hour
Total 
Hours
Non-Refundable Start up Fees:
Protocol Development- Principal 
Investigator $2,400.00 PI variable cost 60.00 40
Protocol Review- Medical Director $500.00
Medical 
Director variable cost 250.00 2
Site Evaluation $240.00 Department variable cost 60.00 4
IRB/Regulatory Document Preparation 
and Submission $960.00 PI variable cost 60.00 16
Contract Preparation and Budget 
Development/Negotiation $440.00 Finance variable cost 55.00 8
Study Preparation and Set-up:  pre 
enrollment $2,400.00 PI variable cost 60.00 40
Pharmacy Preparation and Set-up $120.00 Pharmacy variable cost 60.00 2
Site Initiation $240.00 Department variable cost 60.00 4
Ongoing Financial Oversight including 
registration and scheduling, invoicing, 
and monthly/study conclusion financial 
reconciliation $660.00 Finance variable cost 55.00 12
Total Non-refundable Start-up Fees $7,960.00
Principal Investigator
This fee is to be paid immediately 
upon receipt.
Study management and Oversight $9,960.00 PI
10% Time 
and Effort of 
Base Salary 60.00 166
Direct fixed 
cost
On-Going Regulatory Fees 
Performed by the PI
These fees are to be paid 
immediately upon receipt of invoice.
Full Study Title: Reducing Variability Among Multiple Operators Using a Single Technique and 
Fees may vary depending on IRB used
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Regulatory Fees           
Annual Reviews- Preparation and 
Submission $480.00 PI variable cost 60.00 8 
Changes to Research (each item billed 
separately)           
  1. Protocol Amendment/Revisions $240.00 PI variable cost 60.00 4 
  2. Consent Form Modifications $120.00 PI variable cost 60.00 2 
  3. New or Updated 
Recruitment/Retention Materials $120.00 PI variable cost 60.00 2 
  4. Other Changes to Research 
Requiring Board Review $120.00 PI variable cost 60.00 2 
Adverse Event Report Submission $120.00 PI variable cost 60.00 2 
Local SAE Reporting $120.00 PI variable cost 60.00 2 
Study Close Out with IRB $120.00 PI variable cost 60.00 2 
Monitor Visit Fee (per visit) $240.00 PI variable cost 60.00 4 
            
Meetings And Conferences Invoiced 
Fees           
Investigator/ Coordinator Meetings 
(Investigator)-including travel time $480.00   variable cost 60.00 8 
Conference Calls- (Investigator) $60.00   variable cost 60.00 1 
            
Other Fees:           
Query fees will be invoiced by site 
following conclusion of activity.           
Storage box request fee (after final 
study close out visit) 
$100.00 
per 
retrieval    Fixed Cost 100.00 1 
Query request fee per hour (after final 
study close out visit) 
$75.00 
per hour   Fixed Cost 75.00 1 
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Per Patient Budget    
Schedule of 
Activities 
      
Study Costs Cost per 
Unit 
Service Single 
Study 
Visit 
Comments Cost 
per 
Hour 
Total 
Hours 
CLINICAL 
SERVICES: 
      
Informed Consent 30.00 PI x Direct fixed 
cost 
60.00 0.5 
Inclusion/Exclusion 15.00 PI x Direct fixed 
cost 
60.00 0.25 
Vital Signs 30.00 Nurse 
Assistant 
x Direct fixed 
cost 
30.00  
Height and Weight included 
on VS 
charge * 
Nurse 
Assistant 
x Direct fixed 
cost 
* * 
Pulse Oximetry 
Testing 
included 
in VS 
charge * 
Nurse 
Assistant 
x Direct fixed 
cost 
* * 
Spirometry  119.00   Direct fixed 
cost 
119.00  
Medical, Surgical 
History 
15.00 PI x Direct fixed 
cost 
60.00 0.25 
Physical Exam- 
Brief 
15.00 PI x Direct fixed 
cost 
60.00 0.25 
Skin Prick Testing 408.00 SPT 
Operator 
x Direct fixed 
cost 
408.00 34.00 
x 12 
tests 
Skin Prick Test 
Recording 
included 
in SPT 
charge 
above ** 
SPT 
Operator 
x Direct fixed 
cost 
** ** 
Adverse Event 
Collection 
15.00 PI x Direct fixed 
cost 
60.00 0.25 
Concomitant 
Medication 
Collection 
15.00 PI x Direct fixed 
cost 
60.00 0.25 
LABORATORY 
TESTS 
      
Review previous 
RAST testing 
30.00 PI x Direct fixed 
cost 
60.00 0.5 
       
Questionnaires:       
Source Document 30.00 PI  Direct fixed 60.00 0.5 
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cost 
       
Pharmacy:       
SPT Tray 
Dispensing- per 
dispense 
44.00 Pharmacy x Direct fixed 
cost 
44.00 1 
SPT Tray 
Accountability- per 
dispense 
44.00 Pharmacy x Direct fixed 
cost 
44.00 1 
       
Patient Expense       
Patient Expense 
(parking, stipend) 
 Patient none N/A none  
       
Facility Fee:       
Clinic Visit - 
(facility fee) 
156.00 Facility x Direct fixed 
cost 
156.00 1 
       
Study Personnel 
Costs: 
      
SPT Operator 18.00 SPT 
Operator 
x Direct fixed 
cost 
18.00 1 
Principal 
Investigator  
60.00 PI x Direct fixed 
cost 
60.00 1 
Additional  
Personnel 
 other     
       
Total Per Patient 
Direct Cost 
      
Total Study 26% 
Indirect Cost 
     23.23
% 
Total Per Patient 
Cost 
      
       
Total Study Cost- 
Enrolling 68 
Patients 
     68 
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Fixed 
Vari
able 
   IRB Fees       
   
 
Fixed Costs 
 
200.00 0.00 
   
 
Variable 
Costs 
 
0.00 0.00 
   Non-Refundable Startup Costs     
   
 
Fixed Costs 
 
9,960.00 
    
 
Variable 
Costs 
  
7,96
0.00 
   Per Patient Budget- Total Study     
   
 
Fixed Costs 
 
70,992.00 
    
 
Variable 
Costs 
  
16,4
91.4
4 
   
Sub Total     81,152.00 
24,4
51.4
4 
   
        Total Study Costs 105,603.44 
     
        
        
 In the clinical setting, SPT has a direct cost of 34.00 per prick. 34.00 
direct 
cost per 
SPT 
Once the study is complete, the costs will be offset   3,106 clinical SPT   
  when 3106 SPT are complete         
On average each patient has 20 SPT at a given visit,    20 SPT per patient 
  taking approximately 155 patients to recoup costs. 155 
patients to offsite 
study costs 
On average, there are 50 patients each week requiring SPT 50 patients/week 
Time in weeks to recover costs     3 weeks   
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Appendix E 
 
Regis University Institutional Review Board Approval Letter 
 
 
uNIVERSITY 
Jul) 23.2014 
Eli~beth Lsterl 
1400 Jackson Street 
Den' cr. CO 80206 
RE: IRll #: 14-236 
Dear Dr. bterl: 
Ac1demk: Grants 
IRB- RfGIS L'IIVERSITY 
3333 ReguJ Bou~ard H--4 
o.nv.r Cotot8do 80221·1099 
303 .... ss.420CS 
303-964-5528 FAX 
-'"""-
Your application to the R<-gis IRil for )OUr project ... Reducing Variabihty among Multo pie 
Operators Using a Si ngle Technique and Device for Skin Prick Testing in Children." \\US 
approved as an exp..'llited stud) on Jul) 18. 2014. It is appro\ed per OHRP CategOI) of Research 
#Ill. 
If changes arc made in the research plan that significant!) alter the imohcment of human 
subjects from that \\hich "as appro,ed in the named application. the ne\\ research plan must be 
resubmitted to the Regis IRil for approval. Projects \\hich continue beyond one )Car from their 
staning date require IRB continuation"" ic\\. The continuation ;hould be requested 30 da)s 
prior to the one )Car anni, crsai) date of the appro,cd project's stan date. A completion report of 
the linding> of this stud) should be sent to the IRI3. 
In addition. it is the rcsponsibilit) of the principal ill\CStigntor to prompt!) rcpon to the IRil any 
injuries to human subjects and;or an) unanticipated problems \\ithin the scope of the apprO\ed 
research \\hich rna) pose ris~ to human ;ubjects. I astl). a final rcpon >hould be submitted at 
completion of the project and it b the responsibility of the investigator to tnaintain signed 
cono;cnt documents for a period of three ) cars after the conclusion of the research. 
Sincere!). 
CVu..t~~ 
Patsy McGuire Cullen. PhD. P\JP-BC 
Chair. Institutional Re' ic" Board 
Professor & Director 
Doctor of Nursing Practice & Nurse Practitioner Programs 
Loretto lleights School ofl\ursing 
Regis Unh-crsit) 
cc. Dr. Em in Gelfand 
A JESUIT UNIVERSITY 
63 
 
 
 
Appendix F 
 
National Jewish Health Letter of Support 
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Appendix G 
 
Research Study Forms 
 
  
65 
 
 
 
 
 
 
  
~·National Jewi;~h J2 Health 
Seitt~;:t T1aulomi'tg \ lit ' 
IRB Number· HS 1826 
NATIONAL JEWISH HEAL T'H 
Na110nal JrHlth Health IRB 
APPROVAL 
03te () 3 /?Jtl:l.tzt>l s.,.., t<JV 
I_NiiOR.MED CON'SENT YOR.\1 FOR R£S£ARCH WITH HUMAN SUBJECTS 
Prot0«1l Titl~1 Reducing Vnri11biliry Amons Multiple Ope111torS Uung a Single-Tedutiq~~~e and 
~itt for Slt:ln Prick Tescing i.n Children 
rri•c::ipal la\'tifiptor: Pia Haut. MD 
Vcnkln Ottt: t.tan::h IS, 2014 
14 Hou Centllet Number: J0>-398•1239 
You rut being invited to pan:icipMc inn m~n:h study. Rc5¢irth $ti.DdK5 indu<k only people 
Vli\o choose 10 take P"f1. Plt:.UC take your time rnld:i ng 11 dt"Ci:dl(lfl. t•ecl free to discu.'IS i! with 
your friends. family, and doc~ Before ag:recing to cake part in lhis tCsal.t('.h study. it is 
itnp011at1tlhat you n:&d lhilconsenlllnd authoriution fonn btCIIU5e it de9cribc$1be study omd 
any oflhc ri5ks that it may in\'OI'o"e. No guansntMs OC' promises tan~ mad.: regtlrding you1 
c.xptrk.nce io the scud)'. Plt89e ask the study dc!c:cor or the study staff \Oex:p&ain any ""'OrdS. ideas, 
oc infoon~tion not dear 10 yo1.1. 
Ln lhis conscn1 and authorization form. ")too". alv."'I)'.S refers to the 5'1bjcc.c. If )"'U are a leplly 
authori~ rcproentl!lllive (such as the (IIIJenl), remember lh3.1 '")'buM rde~ 10 the $1ud)' 
p:srticlpant. 
Willy b thi1 s1udy b~i:n.a do.r? 
You are being illi:d 10 roke part in 11 rt!Ca.1dl study ofltam mort shout No'<l ski" pridr: test 
devices atld how OpcralotS use the devioes to find out wh.M:b one device and .ec:brliquc works best 
in chiklral. Yov ~ bcins Q.1ked to be in thill study beolusc yDU ~~:tc :t cunent p!lllient ttl Nmiom!l 
Jewish H~lth's NJ4Kids l'mgrarn and are bctwt'en dk ages of I )'tar at~d 16 years. 
A common diuanc:~stic: prc,JCedure during the initial evt~.l1:3tkln 3nd an. gain; tollow.up care far a 
pers!MI whh allergledl~. Js the skin prlct test. This test involvts placing aUerg_cn 90-tutioos on 
the skin <111d dtCII pricked usinc' dispowbledcwice. The ~suk:s oftlte skin prick te$1 provide 
vuluahle inform11tian u.'led to •:onfirm diB{!;tiOSts 3nd dt\<tlop tmtmmt plans. Skin priek temin~ 
is a by tcsl in idc.ntil}'ing aiJergcnsc.UJing aiJergie .sympwms. pres«ibed immUJXXbc:repy 
tR'Illment, and avoidnna:: dieiS. 
This study will eomJ)Qit'e twodiffemtt skin prick test do:viocs usiQg three different ~cbniqucs 
iDCiudinj: 
• Duotip (Lioc:oln Diag.no5(ics) bil'ulcllkd plaslic needle usi!ll pric:k/lifi t«IWquc 
• Ouolip (UI'Jroln DSa~sdcs) biflutared plaslie oeodJe using twist tedul!que 
• Quinlip (Holli!lt«-Stier) stMI IlltiOet using punel1 rec:hn3que 
INFORMED CONSENT AND HIPAA AUTHORJZA nON FORM 
Marth 15.2014 P~ge 1 of 6 ll'!iljOI$ _ _ 
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Other people in this study 
 
Up to 68 local subjects with will be enrolled in this research study at National Jewish Health. 
This study will not done at any other clinic or hospital. Taking part in this study is completely 
voluntary.  You do not have to participate if you don't want to.  You may also leave the study at 
any time.  If you leave the study before it is finished, there will be no penalty to you, and you 
will not lose any benefits to which you are otherwise entitled.  
What happens if I join this study? 
If you agree to join the study, you will be asked to sign this form. Next the following information 
will be obtained during the single study visit:  
Enrollment/Study Visit 1  
1. Demographics: age at entry, date of birth, gender, race/ethnicity. 
2. Clinical Presentation: brief history of allergic symptoms, signs, age at onset, initial 
interventions 
3. Current Medications and Diet History 
4. Brief Physical examination: Measurements: vital signs; Appearance: skin assessment;  
5. Skin Prick Tests: using Duotip prick, Duotip twist techniques and Quintip punch 
technique. A total of 12 skin prick tests will be completed on your back and recorded 15 
minutes later. Each device will be tested using two histamine solutions (positive control 
and expected to react during test) and two glycerol-saline solutions (negative control and 
expected to not react during test), in three vertical columns and spaced equally apart. The 
operator and person recording the result will not know what solution has been placed 
where. This is called being "blinded" to the test.  
 
Table - Study Visit 
The single study visit will include the following: 
EVALUATION VISIT 1 
Informed Consent X 
Eligibility X 
Medical History X 
Medication History X 
Brief Physical Examination X 
Skin Prick Tests X 
Once the skin prick tests are completed, your participation in the study is complete. The duration of 
the study visit will last approximately 30 minutes and the 12 skin prick tests will take less than 2 
minutes to complete and recorded 15 minutes later. 
What are the possible discomforts or risks? 
Discomforts you may experience while in this study include brief minimal localized site pain is 
associated with the skin prick test procedure which will resolve immediately without treatment 
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once the prick is completed. No additional treatment is necessary to resolve pain. Histamine 
solution (10 mg/mL; Hollister-Stier, Spokane, Wash) as the positive control will cause itching at 
the site. After recording the results after 15 minutes, your back will be washed with warm water 
and the itching should resolve quickly without further treatment. 
 
There is a potential risk of loss of confidentiality, but we will do everything to maintain the 
confidentiality of your personal information by keeping all research records and results in a 
locked file cabinet within a locked office of the principal investigator.  However, confidentiality 
cannot be guaranteed. 
 
The study may include risks that are unknown at this time. 
What are the possible benefits of the study? 
This study is designed for the researcher to learn more about the two skin prick test devices and 
the three different ways that we use them. 
 
This study is not designed to treat any illness or to improve your health.  Also, there may be 
risks, as discussed in the section describing the discomforts or risks. 
 
Are there alternative treatments?  
 
You may elect to not participate in the study.  
 
The treating clinician may be both your health care provider and the investigator for this study. 
This clinician is interested both in your clinical welfare and in the conduct of this study. Before 
entering this study, or at any time during the study, you may ask for a second opinion about your 
care from another clinician who is not associated in any way with the study. 
 
Will I be paid for being in the study?   
 
You will not be paid to be in the study.  
 
Will I have to pay for anything? 
 
It will not cost you anything to be in the study. 
 
Is my participation voluntary? 
 
Taking part in this study is voluntary.  You have the right to choose not to take part in this study.  
If you choose to take part, you have the right to stop at any time.  If you refuse or decide to 
withdraw later, you will not lose any benefits or rights to which you are entitled.  
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What happens if I am injured or hurt during the study?  
In the event of an injury or illness resulting from your participation in this research study, your 
study doctor will assist you in receiving appropriate health care, including first aid, emergency 
treatment and follow-up care either at National Jewish Health or another appropriate health care 
facility. If medical costs are incurred, your insurance company may be billed. In accordance with 
general policy, National Jewish Health makes no commitment to provide free medical care of 
compensation for injury or illness resulting from your participation in this study. By signing this 
form you have not given up your legal rights. For further information, please contact Pia Hauk, 
MD or Elizabeth Esterl DNP, RN, investigators for this study.  They can be reached at phone 
number is 303-398-1239.  
 
If you believe you have experienced any study related illness, adverse event, or injury, you must 
notify the study doctor as soon as possible.  
 
 This has been explained to me and all my questions have been answered 
 
______   Subject/ Parent/Legal Guardian Initials 
 
 
Who do I call if I have questions? 
 
The researchers carrying out this study are Pia Haul, MD and Elizabeth Esterl DNP, RN. You 
may ask any questions you have now. If you have questions, concerns, or complaints later, you 
may call Dr. Hauk or Elizabeth Esterl at 303-398-1239. You will be given a copy of this form to 
keep.   
 
You may have questions about your rights as someone in this study. You can call Dr. Hauk or 
Elizabeth Esterl with questions.  You can also call the responsible Institutional Review Boards at 
National Jewish Health and Regis University.  You can call them at 303-398-1477 (NJH) and 
303-934-3616 (Regis University) or email Regis University IRB at IRB@regis.edu.  
 
Who will see my research information? 
 
National Jewish Health and Regis University have rules to protect information about you. 
Federal and state laws including the Health Insurance Portability and Accountability Act 
(HIPAA) also protect your privacy.   This part of the consent form tells you what information 
about you may be collected in this study and who might see or use it.   
The institutions involved in this study include: 
 National Jewish Health 
 Regis University 
 
We cannot do this study without your permission to see, use and give out your information.  You 
do not have to give us this permission.  If you do not, then you may not join this study.   
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We will see, use and disclose your information only as described in this form and in our Notice 
of Privacy Practices; however, people outside National Jewish Health and Regis University may 
not be covered by this obligation. 
 
We will do everything we can to maintain the confidentiality of your personal information but 
confidentiality cannot be guaranteed. At minimum, we will remove identifying data and use 
coding for your information. We will also keep your records in a locked office. All records 
relating to research that is conducted will be retained for at least three years after completion of 
the research.  
 
The use and disclosure of your information has no time limit.  You can cancel your permission to 
use and disclose your information at any time by writing to the study’s Principal Investigator 
(PI), at the name and address listed below.  If you do cancel your permission to use and disclose 
your information, your part in this study will end and no further information about you will be 
collected.  Your cancellation would not affect information already collected in this study.   
  Pia Hauk, MD      Elizabeth Esterl DNPc, RN 
  Principal Investigator     Co-Investigator 
    National Jewish Health- NJ4Kids Program 
    1400 Jackson Street A220 
    Denver, Colorado 80206 
    303-398-1239 
 
Both the research records that identify you and the consent form signed by you may be looked at 
by others who have a legal right to see that information, such as:   
 Federal offices such as the Food and Drug Administration (FDA) and the Office of 
Human Research Protections (OHRP) that protect research subjects like you. 
 The Institutional Review Boards that are responsible for overseeing this research 
 The principal investigator and study team associated with this study. 
 Officials at the institution where the research is conducted and officials at other 
institutions involved in this study who are in charge of making sure that we follow all of 
the rules for research 
 
We might talk about this research study at meetings.  We might also print the results of this 
research study in relevant journals.  But we will always keep the names of the research subjects, 
like you, private.  
 
You have the right to request access to your personal health information from the Investigator.  
 
Information about you that will be seen, collected, used and disclosed in this study: 
 Name and Demographic Information (age, sex, ethnicity, address, phone number, etc. 
 Portions of your previous and current Medical Records that are relevant to this study, 
including but not limited to Diagnosis (es), History and Physical, Medication History, 
Diet History, Laboratory Results, Skin Prick Test results 
 Research Visit and Research Test record 
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What happens to Data that is collected is collected in this study? 
 
Coded data collected in this study will be stored in a secure, password protected research 
database. If you decide to withdraw from this study, data collected up to this time will be kept 
and used for analysis. 
Agreement to be in this study and use my data 
I have read and initialed each page of this informed consent and HIPAA authorization form (or it 
was read to me).  I was informed about the possible risks and benefits of being in this study.  I 
know that being in this study is voluntary.  I choose to be in this study.  I know I can stop being 
in this study at any time.  I will get a copy of this form after it is signed. 
 
Patient Signature:         Date:    
Print Name: ________________________________________________________ 
______________________________________________    Date_________ 
Parent/Legally Authorized Representative/ Proxy Decision Maker Signature 
 
Print Name: __________________________________________________________ 
___________________________________________________     Date: ________ 
Consent form explained by: Signature             
 
 
Print Name: _____________________________________________________   
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Can I ask Questions? 
I can ask questions about the study now.  These questions will be answered now.  If I think of 
any questions later, I’ll be able to ask them too.  I will get answers to those questions as well.   
 
If I want to, I can call: 
 Pia Hauk, MD      Elizabeth Esterl DNPc, RN 
Principal Investigator      Co-Investigator 
   National Jewish Health- NJ4Kids Program 
   1400 Jackson Street 
   Denver, Colorado 80204 
   303-398-1239 
 
 
Do I Have to Do This? 
I know that I do not have to be in this study. No one will be mad at me if I say no.  
 
I want to be in the study at this time.      YES        NO 
 
I will get a copy of this form to keep. 
 
 
 
Child’s Printed Name:___________________________________________________ 
 
Child’s Signature:________________________________________Date__________ 
 
 
 
Parent/Legal Guardian Printed Name:_____________________________________ 
 
Parent/Legal Guardian Signature:__________________________ Date__________ 
 
 
I have explained the research at a level that is understandable by the child and believe that 
the child understands what is expected during this study. 
 
 
Printed Name of Person Obtaining Assent__________________________________ 
 
Signature of Person Obtaining Assent:________________________Date:__________ 
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 Duotip (Lincoln Diagnostics) bifurcated plastic needle using twist technique  
 Quintip (Hollister-Stier) steel lancet using punch technique 
 
Other people in this study 
 
Up to 68 local subjects with will be enrolled in this research study at National Jewish Health. 
This study will not be done at any other clinic or hospital. Taking part in this study is completely 
voluntary.  You do not have to participate if you don't want to.  You may also leave the study at 
any time.  If you leave the study before it is finished, there will be no penalty to you, and you 
will not lose any benefits to which you are otherwise entitled.  
What happens if I join this study? 
If you agree to join the study, you will be asked to sign this form. Next, the following 
information will be obtained during the single study visit:  
Enrollment/Study Visit 1  
6. Demographics: age at entry, date of birth, gender, race/ethnicity. 
7. Clinical Presentation: brief history of allergic symptoms, signs, age at onset, initial 
interventions 
8. Current Medications and Diet History 
9. Brief Physical examination: Measurements: vital signs; Appearance: skin assessment;  
10. Skin Prick Tests: using Duotip prick, Duotip twist techniques and Quintip punch 
technique. A total of 12 skin prick tests will be completed on your back and recorded 15 
minutes later. Each device will be tested using two histamine solutions (positive control 
and expected to react during test) and two glycerol-saline solutions (negative control and 
expected to not react during test), in three vertical columns and spaced equally apart. The 
operator and person recording the result will not know what solution has been placed 
where. This is called being "blinded" to the test.  
 
Table - Study Visit 
The single study visit will include the following: 
EVALUATION VISIT 1 
Informed Consent X 
Eligibility X 
Medical History X 
Medication History X 
Brief Physical Examination X 
Skin Prick Tests X 
Once the skin prick tests are completed, your participation in the study is complete. The duration of 
the study visit will last approximately 30 minutes and the 12 skin prick tests will take less than 2 
minutes to complete and recorded 15 minutes later. 
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What are the possible discomforts or risks? 
Discomforts you may experience while in this study include brief minimal localized site pain is 
associated with the skin prick test procedure which will resolve immediately without treatment 
once the prick is completed. No additional treatment is necessary to resolve pain. Histamine 
solution (10 mg/mL; Hollister-Stier, Spokane, Wash) as the positive control will cause itching at 
the site. After recording the results after 15 minutes, your back will be washed with warm water 
and the itching should resolve quickly without further treatment. 
 
There is a potential risk of loss of confidentiality, but we will do everything to maintain the 
confidentiality of your personal information by keeping all research records and results in a 
locked file cabinet within a locked office of the principal investigator.  However, confidentiality 
cannot be guaranteed. 
 
The study may include risks that are unknown at this time. 
What are the possible benefits of the study? 
This study is designed for the researcher to learn more about the two skin prick test devices and 
the three different ways that we use them. 
 
This study is not designed to treat any illness or to improve your health.  Also, there may be 
risks, as discussed in the section describing the discomforts or risks. 
 
Are there alternative treatments?  
 
You may elect to not participate in the study.  
 
The treating clinician may be both your health care provider and the investigator for this study. 
This clinician is interested both in your clinical welfare and in the conduct of this study. Before 
entering this study, or at any time during the study, you may ask for a second opinion about your 
care from another clinician who is not associated in any way with the study. 
 
Will I be paid for being in the study?   
 
You will not be paid to be in the study.  
 
Will I have to pay for anything? 
 
It will not cost you anything to be in the study. 
 
Is my participation voluntary? 
                                                                                                                                                   
Taking part in this study is voluntary.  You have the right to choose not to take part in this study.  
If you choose to take part, you have the right to stop at any time.  If you refuse or decide to 
withdraw later, you will not lose any benefits or rights to which you are entitled.  
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What happens if I am injured or hurt during the study?  
In the event of an injury or illness resulting from your participation in this research study, your 
study doctor will assist you in receiving appropriate health care, including first aid, emergency 
treatment and follow-up care either at National Jewish Health or another appropriate health care 
facility. If medical costs are incurred, your insurance company may be billed. In accordance with 
general policy, National Jewish Health makes no commitment to provide free medical care of 
compensation for injury or illness resulting from your participation in this study. By signing this 
form you have not given up your legal rights. For further information, please contact Pia Hauk, 
MD or Elizabeth Esterl DNPc, RN, investigators for this study.  They can be reached at phone 
number 303-398-1239.  
 
If you believe you have experienced any study related illness, adverse event, or injury, you must 
notify the study doctor as soon as possible.  
 
 This has been explained to me and all my questions have been answered 
 
______   Subject/ Parent/Legal Guardian Initials 
 
 
Who do I call if I have questions? 
 
The researchers carrying out this study are Pia Hauk, MD and Elizabeth Esterl DNPc, RN. You 
may ask any questions you have now. If you have questions, concerns, or complaints later, you 
may call Dr. Hauk or Elizabeth Esterl at 303-398-1239. You may also call Dr. Diane Ernst, 
Regis University, DNP student project advisor for co-investigator, Elizabeth Esterl at 303-964-
5768 or dernst@regis.edu.   
 
You may have questions about your rights as someone in this study. You can call Dr. Hauk or 
Elizabeth Esterl with questions.  You can also contact the responsible Institutional Review 
Boards (IRB) at National Jewish Health and Regis University.  You can call the National Jewish 
Health IRB at 303-398-1477 and/or Regis University IRB at 303-458-4206 or email at 
irb@regis.edu.  
 
Who will see my research information? 
 
National Jewish Health and Regis University have rules to protect information about you. 
Federal and state laws including the Health Insurance Portability and Accountability Act 
(HIPAA) also protect your privacy.   This part of the consent form tells you what information 
about you may be collected in this study and who might see or use it.   
The institutions involved in this study include: 
 National Jewish Health 
 Regis University, Denver, Colorado 
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We cannot do this study without your permission to see, use and give out your information.  You 
do not have to give us this permission.  If you do not give us your permission, then you may not 
join this study.   
 
We will see, use and disclose your information only as described in this form and in our Notice 
of Privacy Practices; however, people outside National Jewish Health and Regis University may 
not be covered by this obligation. 
 
We will do everything we can to maintain the confidentiality of your personal information but 
confidentiality cannot be guaranteed. At minimum, we will remove identifying data and use 
coding for your information. We will also keep your records in a locked office. All records 
relating to research that is conducted will be retained for at least three years after completion of 
the research.  
 
The use and disclosure of your information has no time limit.  You can cancel your permission to 
use and disclose your information at any time by writing to the study’s Principal Investigator 
(PI), at the name and address listed below.  If you do cancel your permission to use and disclose 
your information, your part in this study will end and no further information about you will be 
collected.  Your cancellation would not affect information already collected in this study.   
  Pia Hauk, MD      Elizabeth Esterl DNPc, RN 
  Principal Investigator     Co-Investigator 
    National Jewish Health- NJ4Kids Program 
    1400 Jackson Street A220 
    Denver, Colorado 80206 
    303-398-1239 
 
Both the research records that identify you and the consent form signed by you may be looked at 
by others who have a legal right to see that information, such as:   
 Federal offices such as the Food and Drug Administration (FDA) and the Office of 
Human Research Protections (OHRP) that protect research subjects like you. 
 The Institutional Review Boards that are responsible for overseeing this research 
 The principal investigator and study team associated with this study. 
 Officials at the institution where the research is conducted and officials at other 
institutions involved in this study who are in charge of making sure that we follow all of 
the rules for research 
We might talk about this research study at meetings.  We might also print the results of this 
research study in relevant journals.  However, we will always keep the names of the research 
subjects, like you, private.  
 
You have the right to request access to your personal health information from the Investigators.  
 
Information about you that will be seen, collected, used and disclosed in this study: 
 Name and Demographic Information (age, sex, ethnicity, address, phone number, etc.) 
78 
 
 
 
 Portions of your previous and current Medical Records that are relevant to this study, 
including but not limited to Diagnosis (es), History and Physical, Medication History, 
Diet History, Laboratory Results, Skin Prick Test results 
 Research Visit and Research Test record 
 
What happens to data that is collected in this study? 
 
Coded data collected in this study will be stored in a secure, password protected research 
database. If you decide to withdraw from this study, data collected up to this time will be kept 
and used for analysis.  
Agreement to be in this study and use my data 
I have read and initialed each page of this informed consent and HIPAA authorization form (or it 
was read to me).  I was informed about the possible risks and benefits of being in this study.  I 
know that being in this study is voluntary.  I choose to be in this study.  I know I can stop being 
in this study at any time.  I will get a copy of this form after it is signed. 
 
Patient Signature:         Date:         
Print Name: ________________________________________________________ 
______________________________________________    Date_________ 
Parent/Legally Authorized Representative/ Proxy Decision Maker Signature 
Print Name: __________________________________________________________ 
___________________________________________________     Date: ________ 
Consent form explained by: Signature             
Print Name: _____________________________________________________   
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________________________________________________________________________ 
 
Informed Consent Verification 
a. Was the subject provided ample time and opportunity to inquire about the details of the 
study?                                                                                                                [ ] Yes 
 [ ] No 
b. Were all questions about the trial answered to the satisfaction of the subject?          [ ] Yes 
 [ ] No 
c. Was written Informed Consent obtained prior to study participation?                          [ ] 
Yes  [ ] No 
d. Was a signed copy given to the subject’s parent/legal guardian?                              [ ] Yes 
 [ ] No 
 
 
Signature of person reviewing the informed consent and study information with the 
subject:_________________________________________________________________ 
 
________________________________________________________________________ 
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STUDY VISIT - DATE_________________________ 
 
INCLUSION CRITERIA: 
[ ] Age 1 year to 16 years of either sex and any race 
[ ] English speaking 
[ ] Medications, including but not limited to antihistamines, withheld for appropriate time period 
as per hospital protocol 
 
EXCLUSION CRITERIA 
[ ] Inability to comply with skin prick testing  
[ ] Failure of the family/patient to sign the informed consent and HIPAA authorization form 
 
Patient has met all inclusion & exclusion criteria? [ ] Yes   [ ] No 
 
 
DEMOGRAPHIC DATA: 
 Date of Birth_____________________ 
 
 Race:  [ ] Caucasian  [ ]Asian 
  [ ] Black  [ ] Other –Specify 
   
 Ethnicity: [ ] Hispanic [ ] Non-Hispanic 
 
 Sex: [ ] Male  [ ] Female 
 
 
WEIGHT: ____________________kilograms [ ] Not Done 
HEIGHT: ____________________centimeters [ ] Not Done 
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SIGNIFICANT MEDICAL HISTORY FOR ALLERGIC DISEASE  
 
[ ] Asthma 
   
[ ] Food Allergy 
 Food Name   Type of Reaction 
1. _________________________________________________________________ 
2. _________________________________________________________________ 
3. _________________________________________________________________ 
4. _________________________________________________________________ 
5. _________________________________________________________________ 
6. _________________________________________________________________ 
7. _________________________________________________________________ 
8. _________________________________________________________________ 
9. _________________________________________________________________ 
10. _________________________________________________________________ 
 
[ ] Drug Allergy 
 
DRUG ALLERGIES: 
Drug Name/ Class   Type of Reaction 
11. _________________________________________________________________ 
12. _________________________________________________________________ 
13. _________________________________________________________________ 
14. _________________________________________________________________ 
15. _________________________________________________________________ 
16. _________________________________________________________________ 
17. _________________________________________________________________ 
18. _________________________________________________________________ 
19. _________________________________________________________________ 
20. _________________________________________________________________ 
 
[ ] Environmental Allergy 
 
ENVIRONMENTAL ALLERGIES: 
Environmental Allergy  Type of Reaction 
     21. _________________________________________________________________ 
     22. _________________________________________________________________ 
     23. _________________________________________________________________ 
     24. _________________________________________________________________ 
     25. _________________________________________________________________  
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SIGNIFICANT MEDICAL HISTORY 
[ ] Not done   [ ] No significant medical history 
 
DISEASE SYNDROME – SPECIFY   PERTINENT DETAILS 
Non Drug Allergies (specify substance & manifestations) Include surgeries/dates 
1.___________________________ [ ] past   ________________________ 
     [ ] present    ________________________ 
2.___________________________ [ ] past   ________________________ 
     [ ] present    ________________________ 
3.___________________________ [ ] past   ________________________ 
     [ ] present    ________________________ 
4.___________________________ [ ] past   ________________________ 
     [ ] present    ________________________ 
5.___________________________ [ ] past   ________________________ 
     [ ] present    ________________________ 
6.___________________________ [ ] past   ________________________ 
     [ ] present    ________________________ 
7.___________________________ [ ] past   ________________________ 
     [ ] present    ________________________ 
8.___________________________ [ ] past   ________________________ 
     [ ] present    ________________________ 
9.___________________________ [ ] past   ________________________ 
     [ ] present    ________________________ 
10.___________________________ [ ] past   ________________________ 
     [ ] present    ________________________ 
11.___________________________ [ ] past   ________________________ 
     [ ] present    ________________________ 
12.___________________________ [ ] past   ________________________ 
     [ ] present    ________________________ 
13.___________________________ [ ] past   ________________________ 
     [ ] present    ________________________ 
14.___________________________ [ ] past   ________________________ 
     [ ] present    ________________________ 
15.___________________________ [ ] past   ________________________ 
     [ ] present    ________________________ 
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PHYSICAL EXAMINATION: 
[ ] Not done  [ ] Not required at this visit as per protocol 
Date (dd/MMM/yyyy): _ _/_ _ _/ _ _ _ _ 
 
Site       Describe Abnormalities 
General Appearance [ ] Normal 
[ ] Abnormal 
[ ] Not Done 
 
Head [ ] Normal 
[ ] Abnormal 
[ ] Not Done 
 
Lungs [ ] Normal 
[ ] Abnormal 
[ ] Not Done 
 
Heart [ ] Normal 
[ ] Abnormal 
[ ] Not Done 
 
Abdomen [ ] Normal 
[ ] Abnormal 
[ ] Not Done 
 
Skin [ ] Normal 
[ ] Abnormal 
[ ] Not Done 
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SKIN PRICK TESTS-  
 
Operator: _____________________________________________________________ 
 
[ ] Not done  Date (dd/MMM/yyyy): _ _/_ _ _/ _ _ _ _ 
 
Tray used:  [ ] A [ ] B [ ] C 
 
Reading left for right when looking at patient's back: 
Column 1- [ ] Duotip Prick Lift [ ] Quintip Punch [ ] Duotip Twist 
Column 2- [ ] Duotip Prick Lift [ ] Quintip Punch [ ] Duotip Twist 
Column 3- [ ] Duotip Prick Lift [ ] Quintip Punch [ ] Duotip Twist 
DO NOT REVEAL INFORMATION REGARDING TECHNIQUE USED TO ANYONE 
 
15 minutes timer started_________________________________________ (time) 
 
Comments on causes of clinically significant abnormalities: 
 
 
 
CONCOMITANT MEDICATION RECORD: 
 [ ] Not done   
 [ ] None 
Drug Name Indication Route Daily Dose Dates Taken Prestudy 
YES      NO 
     [ ] Yes    [ ] No 
     [ ] Yes    [ ] No 
     [ ] Yes    [ ] No 
     [ ] Yes    [ ] No 
 
ADVERSE EVENTS: 
 [ ] Not done   
 [ ] None 
Adverse Event Relationship to  
Skin Prick Test 
Grade Start Stop Action Taken 
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Skin Prick Test Result Form 
 
Recorder:_______________________________________________________________ 
 
Time: ______________________________skin prick test results recorded.  
 
When looking at the participant's back 
Solution 
Top to Bottom 
Column 1 
Left 
Column 2 
Middle 
Column 3 
Right 
1 wheal: 
 
_______ x _______ 
 
erythema: 
 
_______ x _______ 
 
 
wheal: 
 
_______ x _______ 
 
erythema: 
 
_______ x _______ 
 
wheal: 
 
_______ x _______ 
 
erythema: 
 
_______ x _______ 
 
2 wheal: 
 
_______ x _______ 
 
erythema: 
 
_______ x _______ 
 
 
 
wheal: 
 
_______ x _______ 
 
erythema: 
 
_______ x _______ 
 
wheal: 
 
_______ x _______ 
 
erythema: 
 
_______ x _______ 
 
3 wheal: 
 
_______ x _______ 
 
erythema: 
 
_______ x _______ 
 
wheal: 
 
_______ x _______ 
 
erythema: 
 
_______ x _______ 
 
wheal: 
 
_______ x _______ 
 
erythema: 
 
_______ x _______ 
 
4 wheal: 
 
_______ x _______ 
 
erythema: 
 
_______ x _______ 
 
wheal: 
 
_______ x _______ 
 
erythema: 
 
_______ x _______ 
 
wheal: 
 
_______ x _______ 
 
erythema: 
 
_______ x _______ 
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COORDINATOR COMMENTS 
[ ] Not done   
Date (dd/MMM/yyyy): _ _/_ _ _/ _ _ _ _ 
Time of contact (24 hour clock) _ _: _ _ 
Comments;____________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
Visit completed by _______________________     Date___________________ 
 
 
 
 
 
